Pathology / Tissue/Cellular Phenotype
~ Phenotype / Expression / Risk Spectrum of HBOC
~ Genetics of Breast & Ovarian Cancer

Return to More Current References

Older References


    • 3'UTR shortening and EGF signaling: implications for breast cancer.
    • Akman HB, Oyken M, Tuncer T, Can T, Erson-Bensan AE.
    • Hum Mol Genet. 2015 Dec 15;24(24):6910-20. doi: 10.1093/hmg/ddv391. Epub 2015 Sep 22.
    • Meta-Analysis
    • Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency.
    • Kovac M, Blattmann C, Ribi S, Smida J, Mueller NS, Engert F, Castro-Giner F, Weischenfeldt J, Kovacova M, Krieg A, Andreou D, Tunn PU, Dürr HR, Rechl H, Schaser KD, Melcher I, Burdach S, Kulozik A, Specht K, Heinimann K, Fulda S, Bielack S, Jundt G, Tomlinson I, Korbel JO, Nathrath M, Baumhoer D.
    • Nat Commun. 2015 Dec 3;6:8940. doi: 10.1038/ncomms9940.
    • Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    • Yamashita N, Tokunaga E, Kitao H, Hitchins M, Inoue Y, Tanaka K, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Oda Y, Saeki H, Oki E, Maehara Y.
    • Clin Breast Cancer. 2015 Dec;15(6):498-504. doi: 10.1016/j.clbc.2015.06.009. Epub 2015 Jun 18.
    • BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    • de Juan I, Palanca S, Domenech A, Feliubadaló L, Segura Á, Osorio A, Chirivella I, de la Hoya M, Sánchez AB, Infante M, Tena I, Díez O, Garcia-Casado Z, Vega A, Teulé À, Barroso A, Pérez P, Durán M, Carrasco E, Juan-Fita MJ, Murria R, Llop M, Barragan E, Izquierdo Á, Benítez J, Caldés T, Salas D, Bolufer P.
    • Fam Cancer. 2015 Dec;14(4):505-13. doi: 10.1007/s10689-015-9814-z.
    • Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.
    • Biesma HD, Schouten PC, Lacle MM, Sanders J, Brugman W, Kerkhoven R, Mandjes I, van der Groep P, van Diest PJ, Linn SC.
    • Genes Chromosomes Cancer. 2015 Dec;54(12):734-44. doi: 10.1002/gcc.22284. Epub 2015 Sep 10.
    • Decreased Expression of BRCA2 Accelerates Sporadic Breast Cancer Progression.
    • Saha S, Mandal P, Ganguly S, Jana D, Ayaz A, Banerjee A, Chouhan R, Sarkar DK.
    • Indian J Surg Oncol. 2015 Dec;6(4):378-83. doi: 10.1007/s13193-015-0449-1. Epub 2015 Aug 21.
    • Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
    • Massink MP, Kooi IE, Martens JW, Waisfisz Q, Meijers-Heijboer H.
    • BMC Cancer. 2015 Nov 9;15:877. doi: 10.1186/s12885-015-1880-y.
    • First description of a sporadic breast cancer in a woman with BRCA1 germline mutation.
    • Curtit E, Benhamo V, Gruel N, Popova T, Manie E, Cottu P, Mariani O, Stoppa-Lyonnet D, Pivot X, Stern MH, Vincent-Salomon A.
    • Oncotarget. 2015 Nov 3;6(34):35616-24. doi: 10.18632/oncotarget.5348.
    • Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.
    • McDaniel AS, Stall JN, Hovelson DH, Cani AK, Liu CJ, Tomlins SA, Cho KR.
    • JAMA Oncol. 2015 Nov 1;1(8):1128-1132. doi: 10.1001/jamaoncol.2015.1618.
    • BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.
    • Mohanty SK, Lai JP, Gordon OK, Pradhan D, Bose S, Dadmanesh F.
    • Breast J. 2015 Nov;21(6):596-603. doi: 10.1111/tbj.12494. Epub 2015 Sep 22.
    • Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysis.
    • Guo T, Ren Y, Wang B, Huang Y, Jia S, Tang W, Luo Y.
    • Mol Clin Oncol. 2015 Nov;3(6):1353-1360. Epub 2015 Aug 11.
    • Lipid and Metabolite Deregulation in BRCA1 and BRCA2 Genetic Mutations.
    • Stanwell P, Gluch L.
    • Radiology. 2015 Nov;277(2):614-5. doi: 10.1148/radiol.2015151153.
    • Comment, Letter

    Lipid and Metabolite Deregulation in the Breast Tissue of Women Carrying BRCA1 and BRCA2 Genetic Mutations.

    • DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.
    • Yang RL, Mick R, Lee K, Graves HL, Nathanson KL, Domchek SM, Kelz RR, Zhang PJ, Czerniecki BJ.
    • J Transl Med. 2015 Oct 24;13(1):335. doi: 10.1186/s12967-015-0698-3.
    • miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
    • Vos S, Vesuna F, Raman V, van Diest PJ, van der Groep P.
    • Oncotarget. 2015 Oct 13;6(31):32115-37. doi: 10.18632/oncotarget.5617.
    • High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.
    • Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B.
    • Cancer. 2015 Oct 1;121(19):3422-3427. doi: 10.1002/cncr.29572. Epub 2015 Aug 17.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: HR-low-positive tumors. Treat as TNBC?

    • BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
    • Wiener D, Gajardo-Meneses P, Ortega-Hernández V, Herrera-Cares C, Díaz S, Fernández W, Cornejo V, Gamboa J, Tapia T, Alvarez C, Carvallo P.
    • Breast Cancer Res Treat. 2015 Oct;153(3):669-78. doi: 10.1007/s10549-015-3575-0. Epub 2015 Sep 22.
    • MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers.
    • Maresca L, Spugnesi L, Lodovichi S, Cozzani C, Naccarato AG, Tancredi M, Collavoli A, Falaschi E, Rossetti E, Aretini P, Cervelli T, Galli A, Caligo MA.
    • Eur J Med Genet. 2015 Oct;58(10):531-9. doi: 10.1016/j.ejmg.2015.09.005. Epub 2015 Sep 14.
    • BRCAness in endometrial cancer.
    • Stephan JM, Cohen E, Gonzalez J.
    • Gynecologic Oncology. 2015 Oct;139(1):188. 2015 WAGO ABSTRACTS. doi: 10.1016/j.ygyno.2015.07.044.
    • Conference abstract
    • Loss of heterozygosity in non-traditional cancers occurring in BRCA1 and BRCA2 mutation carriers.
    • McIlwain C, Norquist B, Bernards S, Agnew K, Swisher E.
    • Gynecologic Oncology. 2015 Oct;139(1):200. 2015 WAGO ABSTRACTS. doi: 10.1016/j.ygyno.2015.07.075.
    • Conference abstract
    • BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
    • Severson TM, Peeters J, Majewski I, Michaut M, Bosma A, Schouten PC, Chin SF, Pereira B, Goldgraben MA, Bismeijer T, Kluin RJ, Muris JJ, Jirström K, Kerkhoven RM, Wessels L, Caldas C, Bernards R, Simon IM, Linn S.
    • Mol Oncol. 2015 Oct;9(8):1528-38. doi: 10.1016/j.molonc.2015.04.011. Epub 2015 May 7.
    • A network-based approach to identify disease-associated gene modules through integrating DNA methylation and gene expression.
    • Zhang Y, Zhang J, Liu Z, Liu Y, Tuo S.
    • Biochem Biophys Res Commun. 2015 Sep 25;465(3):437-42. doi: 10.1016/j.bbrc.2015.08.033. Epub 2015 Aug 14.
    • Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes.
    • Cochran RL, Cidado J, Kim M, Zabransky DJ, Croessmann S, Chu D, Wong HY, Beaver JA, Cravero K, Erlanger B, Parsons H, Heaphy CM, Meeker AK, Lauring J, Park BH.
    • Oncotarget. 2015 Sep 22;6(28):25240-51. doi: 10.18632/oncotarget.4595.
    • Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
    • Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, Dubeau L, Cline M, Pan Y, Yi PC, Gareth Evans D, Jacobs IJ, Menon U, Wood CE, Dougall WC.
    • EBioMedicine. 2015 Sep 9;2(10):1331-9. doi: 10.1016/j.ebiom.2015.08.037. eCollection 2015.

    Commentary

    RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers.

    • New insights in the pathophysiology of ovarian cancer and implications for screening and prevention.
    • Nezhat FR, Apostol R, Nezhat C, Pejovic T.
    • Am J Obstet Gynecol. 2015 Sep;213(3):262-7. doi: 10.1016/j.ajog.2015.03.044. Epub 2015 Mar 25.
    • BRCA1 mislocalization associated with breast carcinogenesis and poor prognosis in Taiwanese women.
    • Ho JY, Hsu RJ, Wu CL, Chen SH, Wu MY, Yu JC, Gao HW, Yen AM, Chen HH, Yu CP.
    • Eur J Cancer Prev. 2015 Sep;24(5):407-15. doi: 10.1097/CEJ.0000000000000114.
    • Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.
    • Fleury H, Communal L, Carmona E, Portelance L, Arcand SL, Rahimi K, Tonin PN, Provencher D, Mes-Masson AM.
    • Genes Cancer. 2015 Sep;6(9-10):378-398.
    • Ethnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization.
    • Nakshatri H, Anjanappa M, Bhat-Nakshatri P.
    • Sci Rep. 2015 Aug 27;5:13526. doi: 10.1038/srep13526.
    • Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.
    • Bayraktar S, Qiu H, Liu D, Shen Y, Gutierrez-Barrera AM, Arun BK, Sahin AA.
    • Biomark Cancer. 2015 Aug 18;7:39-49. doi: 10.4137/BIC.S29716. eCollection 2015.
    • Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.
    • Alkner S, Tang MH, Brueffer C, Dahlgren M, Chen Y, Olsson E, Winter C, Baker S, Ehinger A, Rydén L, Saal LH, Fernö M, Gruvberger-Saal SK.
    • Breast Cancer Res. 2015 Aug 5;17(1):102. doi: 10.1186/s13058-015-0608-x.
    • Prospective multicenter cohort study of estrogen and insulin-like growth factor system in BRCA mutation carriers.
    • Kim J, Johnson L, Skrzynia C, Buchanan A, Gracia C, Mersereau JE.
    • Cancer Causes Control. 2015 Aug;26(8):1087-92. doi: 10.1007/s10552-015-0601-9. Epub 2015 May 26.
    • The secondary Müllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters.
    • Singh N, Gilks CB, Wilkinson N, McCluggage WG.
    • Pathology. 2015 Aug;47(5):423-31. doi: 10.1097/PAT.0000000000000291.
    • Review
    • Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Breast Cancer.
    • Lemnrau A, Brook MN, Fletcher O, Coulson P, Tomczyk K, Jones M, Ashworth A, Swerdlow A, Orr N, Garcia-Closas M.
    • Cancer Res. 2015 Jul 15;75(14):2844-50. doi: 10.1158/0008-5472.CAN-14-1692. Epub 2015 May 14.
    • Mammographic density and breast cancer in women from high risk families.
    • Ramón Y Cajal T, Chirivella I, Miranda J, Teule A, Izquierdo Á, Balmaña J, Sánchez-Heras AB, Llort G, Fisas D, Lope V, Hernández-Agudo E, Juan-Fita MJ, Tena I, Robles L, Guillén-Ponce C, Pérez-Segura P, Luque-Molina MS, Hernando-Polo S, Salinas M, Brunet J, Salas-Trejo MD, Barnadas A, Pollán M.
    • Breast Cancer Res. 2015 Jul 11;17:93. doi: 10.1186/s13058-015-0604-1.
    • Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
    • Yan M, Shield-Artin K, Byrne D, Deb S, Waddell N; kConFab Investigators, kConFab, Haviv I, Fox SB.
    • BMC Cancer. 2015 Jul 8;15:506. doi: 10.1186/s12885-015-1522-4.
    • Epidemiological and clinicopathological characteristics of BRCA-positive and BRCA-negative breast cancer patients in Greece.
    • Triantafyllidou O, Vlachos IS, Apostolou P, Konstantopoulou I, Grivas A, Panopoulos C, Dimitrakakis C, Kassanos D, Loghis C, Bramis I, Vlahos N, Yannoukakos D, Fostira F.
    • J BUON. 2015 Jul-Aug;20(4):978-84.
    • DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers.
    • Vaclová T, Gómez-López G, Setién F, Bueno JM, Macías JA, Barroso A, Urioste M, Esteller M, Benítez J, Osorio A.
    • Breast Cancer Res Treat. 2015 Jul;152(2):271-82. doi: 10.1007/s10549-015-3459-3. Epub 2015 Jun 14.
    • Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography.
    • Møller P, Tharmaratnam K, Howell A, Stavrinos P, Sampson S, Wallace A, Maxwell AJ, Hagen AI, Evans DG.
    • Breast Cancer Res Treat. 2015 Jul;152(1):87-94. doi: 10.1007/s10549-015-3448-6. Epub 2015 Jun 3.
    • Family history and outcome of young patients with breast cancer in the UK (POSH study).
    • Eccles BK, Copson ER, Cutress RI, Maishman T, Altman DG, Simmonds P, Gerty SM, Durcan L, Stanton L, Eccles DM; POSH Study Steering Group.
    • Br J Surg. 2015 Jul;102(8):924-35. doi: 10.1002/bjs.9816. Epub 2015 May 20.
    • Discordant pattern of BRCA1 gene epimutation in blood between mothers and daughters.
    • Wojdacz TK, Harari F, Vahter M, Broberg K.
    • J Clin Pathol. 2015 Jul;68(7):575-7. doi: 10.1136/jclinpath-2015-202982. Epub 2015 Apr 15.
    • Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine.
    • Murria R, Palanca S, de Juan I, Alenda C, Egoavil C, Seguí FJ, García-Casado Z, Juan MJ, Sánchez AB, Segura Á, Santaballa A, Chirivella I, Llop M, Pérez G, Barragán E, Salas D, Bolufer P.
    • Am J Cancer Res. 2015 Jun 15;5(7):2330-43. eCollection 2015.
    • Plasma Proteomic Profiling in Hereditary Breast Cancer Reveals a BRCA1-Specific Signature: Diagnostic and Functional Implications.
    • Scumaci D, Tammè L, Fiumara CV, Pappaianni G, Concolino A, Leone E, Faniello MC, Quaresima B, Ricevuto E, Costanzo FS, Cuda G.
    • PLoS One. 2015 Jun 10;10(6):e0129762. doi: 10.1371/journal.pone.0129762.
    • Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers.
    • Chiang HC, Elledge R, Larson P, Jatoi I, Li R, Hu Y.
    • Breast Cancer (Auckl). 2015 Jun 2;9:25-9. doi: 10.4137/BCBCR.S26774. eCollection 2015.
    • Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways.
    • Heublein S, Mayr D, Meindl A, Angele M, Gallwas J, Jeschke U, Ditsch N.
    • PLoS One. 2015 Jun 1;10(6):e0127072. doi: 10.1371/journal.pone.0127072. eCollection 2015.
    • BRCA1 mutation site may be linked with nuclear DNA ploidy in BRCA1-mutated ovarian carcinomas.
    • Aghmesheh M, Saxena A, Niknam F.
    • Asia Pac J Clin Oncol. 2015 Jun;11(2):135-41. doi: 10.1111/ajco.12310. Epub 2014 Nov 27.
    • The effect of oral 3,3'-diindolylmethane supplementation on the 2:16α-OHE ratio in BRCA1 mutation carriers.
    • Nikitina D, Llacuachaqui M, Sepkovic D, Bradlow HL, Narod SA, Kotsopoulos J.
    • Fam Cancer. 2015 Jun;14(2):281-6. doi: 10.1007/s10689-015-9783-2.
    • Lipid and Metabolite Deregulation in the Breast Tissue of Women Carrying BRCA1 and BRCA2 Genetic Mutations.
    • Ramadan S, Arm J, Silcock J, Santamaria G, Buck J, Roy M, Leong KM, Lau P, Clark D, Malycha P, Mountford C.
    • Radiology. 2015 Jun;275(3):675-82. doi: 10.1148/radiol.15140967. Epub 2015 Mar 3.

    Comment / Letter

    Lipid and Metabolite Deregulation in BRCA1 and BRCA2 Genetic Mutations.

    • Whole-genome characterization of chemoresistant ovarian cancer.
    • Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.
    • Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410.
    • Pathologic findings at risk-reducing surgery.
    • Mourits MJ, de Bock GH, Hollema H.
    • J Clin Oncol. 2015 May 1;33(13):1514. doi: 10.1200/JCO.2014.59.3376. Epub 2015 Mar 2.

    Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199.

    Letter

    Reply to m.j. Mourits et Al.

    • Epigenetic changes in BRCA1-mutated familial breast cancer.
    • Downs B, Wang SM.
    • Cancer Genet. 2015 May;208(5):237-40. doi: 10.1016/j.cancergen.2015.02.001. Epub 2015 Feb 13.
    • Salpingectomy as a means to reduce ovarian cancer risk.
    • Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, Lu KH.
    • Cancer Prev Res (Phila). 2015 May;8(5):342-8. doi: 10.1158/1940-6207.CAPR-14-0293. Epub 2015 Jan 13.

    Comment

    The fallopian tube: from back stage to center stage.

    • Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.
    • Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J.
    • Genes Chromosomes Cancer. 2015 May;54(5):276-87. doi: 10.1002/gcc.22241. Epub 2015 Feb 23.
    • Ovarian cancer survival by tumor dominance, a surrogate for site of origin.
    • Ivanova A, Loo A, Tworoger S, Crum CP, Fan I, McLaughlin JR, Rosen B, Risch H, Narod SA, Kotsopoulos J.
    • Cancer Causes Control. 2015 Apr;26(4):601-8. doi: 10.1007/s10552-015-0547-y. Epub 2015 Mar 13.
    • Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.
    • Massink MP, Kooi IE, van Mil SE, Jordanova ES, Ameziane N, Dorsman JC, van Beek DM, van der Voorn JP, Sie D, Ylstra B, van Deurzen CH, Martens JW, Smid M, Sieuwerts AM, de Weerd V, Foekens JA, van den Ouweland AM, van Dyk E, Nederlof PM, Waisfisz Q, Meijers-Heijboer H.
    • Mol Oncol. 2015 Apr;9(4):877-88. doi: 10.1016/j.molonc.2014.12.012. Epub 2015 Jan 13.
    • Low grade serious carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a "low-grade serous tubal intra-epithelial carcinoma" (STIC) on risk reducing surgery.
    • Chay WY, Horlings HM, Tinker AV, Gelmon KA, Gilks CB.
    • Gynecol Oncol Rep. 2015 Mar 28;12:72-4. doi: 10.1016/j.gore.2015.03.007. eCollection 2015.
    • Evidence for a Dualistic Model of High-grade Serous Carcinoma: BRCA Mutation Status, Histology, and Tubal Intraepithelial Carcinoma.
    • Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, Crum CP, Meserve EE.
    • Am J Surg Pathol. 2015 Mar;39(3):287-93. doi: 10.1097/PAS.0000000000000369.
    • Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases: Further Evidence for the Tubal Origin of High-grade Serous Carcinomas.
    • Gilks CB, Irving J, Köbel M, Lee C, Singh N, Wilkinson N, McCluggage WG.
    • Am J Surg Pathol. 2015 Mar;39(3):357-64. doi: 10.1097/PAS.0000000000000353.
    • Serous Tubal Intraepithelial Carcinoma Localizes to the Tubal-peritoneal Junction: A Pivotal Clue to the Site of Origin of Extrauterine High-grade Serous Carcinoma (Ovarian Cancer).
    • Seidman JD.
    • Int J Gynecol Pathol. 2015 Mar;34(2):112-20. doi: 10.1097/PGP.0000000000000123.
    • Low-level constitutional mosaicism of a de novoBRCA1 gene mutation.
    • Friedman E, Efrat N, Soussan-Gutman L, Dvir A, Kaplan Y, Ekstein T, Nykamp K, Powers M, Rabideau M, Sorenson J, Topper S.
    • Br J Cancer. 2015 Feb 17;112(4):765-768. doi: 10.1038/bjc.2015.14. Epub 2015 Jan 29.
    • MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors.
    • Tanic M, Yanowski K, Gómez-López G, Socorro Rodriguez-Pinilla M, Marquez-Rodas I, Osorio A, Pisano DG, Martinez-Delgado B, Benítez J.
    • Int J Cancer. 2015 Feb 15;136(3):593-602. doi: 10.1002/ijc.29021. Epub 2014 Jun 19.
    • Ultrasonographic characteristics and BI-RADS-US classification of BRCA1 mutation-associated breast cancer in Guangxi, China.
    • Li C, Liu J, Wang S, Chen Y, Yuan Z, Zeng J, Li Z.
    • Int J Clin Exp Med. 2015 Feb 15;8(2):2411-6. eCollection 2015.
    • BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
    • Erturk E, Cecener G, Tezcan G, Egeli U, Tunca B, Gokgoz S, Tolunay S, Tasdelen I.
    • Gene. 2015 Feb 10;556(2):163-9. doi: 10.1016/j.gene.2014.11.047. Epub 2014 Nov 22.
    • The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.
    • Gu Y, Zhang M, Peng F, Fang L, Zhang Y, Liang H, Zhou W, Ao L, Guo Z.
    • Oncotarget. 2015 Feb 10;6(4):2397-406.
    • High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients.
    • Kalniete D, Nakazawa-Miklaševiča M, Štrumfa I, Āboliņš A, Irmejs A, Gardovskis J, Miklaševičs E.
    • Hered Cancer Clin Pract. 2015 Feb 8;13(1):7. doi: 10.1186/s13053-015-0028-z. eCollection 2015.
    • DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
    • Aleskandarany M, Caracappa D, Nolan CC, Macmillan RD, Ellis IO, Rakha EA, Green AR.
    • Breast Cancer Res Treat. 2015 Feb;150(1):81-90. doi: 10.1007/s10549-015-3306-6. Epub 2015 Feb 19.
    • Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer.
    • van Verschuer VM, Hooning MJ, van Baare-Georgieva RD, Hollestelle A, Timmermans AM, Koppert LB, Verhoog LC, Martens JW, Seynaeve C, van Deurzen CH.
    • Hum Pathol. 2015 Feb;46(2):182-90. doi: 10.1016/j.humpath.2014.10.020. Epub 2014 Nov 15.
    • Ovarian cancer risk after salpingectomy: a nationwide population-based study.
    • Falconer H, Yin L, Grönberg H, Altman D.
    • J Natl Cancer Inst. 2015 Jan 27 [2015 Feb;];107(2). pii: dju410. doi: 10.1093/jnci/dju410. Print 2015 Feb.

    Comment / Editorial

    Salpingectomy as a potential ovarian cancer risk-reducing procedure.

    Research snippets.

    News

    • Salpingectomy as a potential ovarian cancer risk-reducing procedure.
    • Poole EM, Rice MS, Crum CP, Tworoger SS.
    • J Natl Cancer Inst. 2015 Jan 27 [2015 Feb;];107(2). pii: dju490. doi: 10.1093/jnci/dju490. Print 2015 Feb.

    Ovarian cancer risk after salpingectomy: a nationwide population-based study.

    • Sister chromatid exchange: A possible approach to characterize familial breast cancer patients.
    • De Pascalis I, Pilato B, Mazzotta A, Dell'Endice TS, Rubini V, Simone G, Paradiso A, Aiello V, Mangia A.
    • Oncol Rep. 2015 Feb;33(2):930-4. doi: 10.3892/or.2014.3628. Epub 2014 Nov 26.
    • Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications.
    • Dubeau L.
    • Transl Cancer Res. 2015 Feb;4(1):3-13.
    • Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked.
    • Niravath P, Eble T, Contreras A, Li M, Franco LM, Rimawi M.
    • Exp Hematol Oncol. 2015 Jan 6;4(1):1. doi: 10.1186/2162-3619-4-1. eCollection 2015.
    • Subtyping of triple-negative breast cancer: Implications for therapy.
    • Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA.
    • Cancer. 2015 Jan 1;121(1):8-16. doi: 10.1002/cncr.28914. Epub 2014 Jul 16.
    • MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis.
    • Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Merla G, Simone G, Tommasi S.
    • Oncotarget. 2015 Jan 1;6(1):471-83.
    • Biological and clinical significance of PARP1 protein expression in breast cancer.
    • Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S, Ellis IO, Rakha EA.
    • Breast Cancer Res Treat. 2015 Jan;149(2):353-62. doi: 10.1007/s10549-014-3230-1. Epub 2014 Dec 21.
    • Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients.
    • Benitez-Buelga C, Sanchez-Barroso L, Gallardo M, Apellániz-Ruiz M, Inglada-Pérez L, Yanowski K, Carrillo J, Garcia-Estevez L, Calvo I, Perona R, Urioste M, Osorio A, Blasco MA, Rodriguez-Antona C, Benitez J.
    • Breast Cancer Res Treat. 2015 Jan;149(2):385-94. doi: 10.1007/s10549-014-3246-6. Epub 2014 Dec 21.
    • Metastatic patterns of breast cancer subtypes: What radiologists should know in the era of personalized cancer medicine.
    • Chikarmane SA, Tirumani SH, Howard SA, Jagannathan JP, DiPiro PJ.
    • Clin Radiol. 2015 Jan;70(1):1-10. doi: 10.1016/j.crad.2014.08.015. Epub 2014 Oct 7.
    • Review
    • Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update.
    • Zeppernick F, Meinhold-Heerlein I, Shih IeM.
    • J Obstet Gynaecol Res. 2015 Jan;41(1):6-11. doi: 10.1111/jog.12550. Epub 2014 Oct 20.
    • Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
    • Duffy MJ, Walsh S, McDermott EW, Crown J.
    • Adv Clin Chem. 2015;71:1-23. doi: 10.1016/bs.acc.2015.05.001. Epub 2015 Jun 23.
    • Review

    Comment / Introductory Journal Article

    Preface.

    • BRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface Epithelial Cells.
    • Woolery KT, Mohamed M, Linger RJ, Dobrinski KP, Roman J, Kruk PA.
    • Biomed Res Int. 2015;2015:652017. doi: 10.1155/2015/652017. Epub 2015 Aug 19.
    • Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.
    • Desai A, Xu J, Aysola K, Akinbobuyi O, White M, Reddy VE, Okoli J, Clark C, Partridge EE, Childs E, Beech DJ, Rice MV, Reddy E, Rao VN.
    • J Gynecol Res. 2015;1(1). pii: 103. Epub 2015 Apr 24.
    • Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
    • Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK, Engel C, Wappenschmidt B, Nevanlinna H, Thomassen M, Southey M, Radice P, Ramus SJ, Domchek SM, Nathanson KL, Lee A, Healey S, Nussbaum RL, Rebbeck TR, Arun BK, James P, Karlan BY, Lester J, Cass I; Breast Cancer Family Registry, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, v O Hansen T, Ejlertsen B, Gerdes AM, Nielsen FC, Dennis J, Cunningham J, Hart S, Slager S, Osorio A, Benitez J, Duran M, Weitzel JN, Tafur I, Hander M, Peterlongo P, Manoukian S, Peissel B, Roversi G, Scuvera G, Bonanni B, Mariani P, Volorio S, Dolcetti R, Varesco L, Papi L, Tibiletti MG, Giannini G, Fostira F, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE Study, Douglas F, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Ong KR, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Ellis S, Godwin AK, Rhiem K, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Steinemann D, Bogdanova-Markov N, Kast K, Varon-Mateeva R, Wang-Gohrke S, Gehrig A, Markiefka B, Buecher B, Lefol C, Stoppa-Lyonnet D, Rouleau E, Prieur F, Damiola F; GEMO Study Collaborators, Barjhoux L, Faivre L, Longy M, Sevenet N, Sinilnikova OM, Mazoyer S, Bonadona V, Caux-Moncoutier V, Isaacs C, Van Maerken T, Claes K, Piedmonte M, Andrews L, Hays J, Rodriguez GC, Caldes T, de la Hoya M, Khan S, Hogervorst FB, Aalfs CM, de Lange JL, Meijers-Heijboer HE, van der Hout AH, Wijnen JT, van Roozendaal KE, Mensenkamp AR, van den Ouweland AM, van Deurzen CH, van der Luijt RB; HEBON, Olah E, Diez O, Lazaro C, Blanco I, Teulé A, Menendez M, Jakubowska A, Lubinski J, Cybulski C, Gronwald J, Jaworska-Bieniek K, Durda K, Arason A, Maugard C, Soucy P, Montagna M, Agata S, Teixeira MR; KConFab Investigators, Olswold C, Lindor N, Pankratz VS, Hallberg E, Wang X, Szabo CI, Vijai J, Jacobs L, Corines M, Lincoln A, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Mai PL, Greene MH, Rennert G, Imyanitov EN, Glendon G, Toland AE, Bojesen A, Pedersen IS, Jensen UB, Caligo MA, Friedman E, Berger R, Laitman Y, Rantala J, Arver B, Loman N, Borg A, Ehrencrona H, Olopade OI, Simard J, Easton DF, Chenevix-Trench G, Offit K, Couch FJ, Antoniou AC; CIMBA.
    • Breast Cancer Res. 2014 Dec 31;16(6):3416. doi: 10.1186/s13058-014-0492-9.
    • Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
    • Spurdle AB, Couch FJ, Parsons MT, McGuffog L, Barrowdale D, Bolla MK, Wang Q, Healey S, Schmutzler R, Wappenschmidt B, Rhiem K, Hahnen E, Engel C, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Ellis S, Frost D, Platte R, Perkins J, Evans D, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Scuvera G, Manoukian S, Bonanni B, Mariette F, Fortuzzi S, Viel A, Pasini B, Papi L, Varesco L, Balleine R, Nathanson KL, Domchek SM, Offitt K, Jakubowska A, Lindor N, Thomassen M, Jensen U, Rantala J, Borg Å, Andrulis IL, Miron A, Hansen T, Caldes T, Neuhausen SL, Toland AE, Nevanlinna H, Montagna M, Garber J, Godwin AK, Osorio A, Factor RE, Terry MB, Rebbeck TR, Karlan BY, Southey M, Rashid M, Tung N, Pharoah P, Blows FM, Dunning AM, Provenzano E, Hall P, Czene K, Schmidt MK, Broeks A, Cornelissen S, Verhoef S, Fasching PA, Beckmann MW, Ekici AB, Slamon DJ, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Chang-Claude J, Flesch-Janys D, Rudolph A, Seibold P, Aittomäki K, Muranen TA, Heikkilä P, Blomqvist C, Figueroa J, Chanock SJ, Brinton L, Lissowska J, Olson JE, Pankratz VS, John EM, Whittemore AS, West DW, Hamann U, Torres D, Ulmer H, Rüdiger T, Devilee P, Tollenaar R, Seynaeve C, Van Asperen CJ, Eccles DM, Tapper WJ, Durcan L, Jones L, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Dwek M, Swann R, Bane AL, Glendon G, Mulligan AM, Giles GG, Milne RL, Baglietto L, McLean C, Carpenter J, Clarke C, Scott R, Brauch H, Brüning T, Ko YD, Cox A, Cross SS, Reed M, Lubinski J, Jaworska-Bieniek K, Durda K, Gronwald J, Dörk T, Bogdanova N, Park-Simon TW, Hillemanns P, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Burwinkel B, Marme F, Surovy H, Yang R, Anton-Culver H, Ziogas A, Hooning MJ, Collée J, Martens J, Tilanus-Linthorst M, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Lindblom A, Margolin S, Joseph V, Robson M, Rau-Murthy R, González-Neira A, Arias J, Zamora P, Benítez J, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Peterlongo P, Zaffaroni D, Barile M, Capra F, Radice P, Teo SH, Easton DF, Antoniou AC, Chenevix-Trench G, Goldgar DE; ABCTB Investigators; EMBRACE Group; GENICA Network; HEBON Group; kConFab Investigators.
    • Breast Cancer Res. 2014 Dec 23;16(6):3419. doi: 10.1186/s13058-014-0474-y.
    • Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
    • Deb S, Wong SQ, Li J, Do H, Weiss J, Byrne D, Chakrabarti A, Bosma T; kConFab Investigators, Fellowes A, Dobrovic A, Fox SB.
    • Br J Cancer. 2014 Dec 9;111(12):2351-2360. doi: 10.1038/bjc.2014.511.
    • MicroRNA expression profiling in male and female familial breast cancer.
    • Pinto R, De Summa S, Danza K, Popescu O, Paradiso A, Micale L, Merla G, Palumbo O, Carella M, Tommasi S.
    • Br J Cancer. 2014 Dec 9;111(12):2361-2368. doi: 10.1038/bjc.2014.535. Epub 2014 Nov 13.
    • Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    • Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS.
    • Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.
    • Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
    • Niskakoski A, Kaur S, Staff S, Renkonen-Sinisalo L, Lassus H, Järvinen HJ, Mecklin JP, Bützow R, Peltomäki P.
    • Epigenetics. 2014 Dec 2;9(12):1577-87. doi: 10.4161/15592294.2014.983374.
    • The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
    • Meisel JL, Hyman DM, Garg K, Zhou Q, Dao F, Bisogna M, Gao J, Schultz ND, Grisham RN, Phillips M, Iasonos A, Kauff ND, Levine DA, Soslow RA, Spriggs DR.
    • Ann Oncol. 2014 Dec;25(12):2372-8. doi: 10.1093/annonc/mdu461. Epub 2014 Oct 3.
    • Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.
    • Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS, Amos C, Gambello M, Ready KJ, Arun B.
    • Breast. 2014 Dec;23(6):770-4. doi: 10.1016/j.breast.2014.08.010. Epub 2014 Sep 16.
    • Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
    • Gupta S, Jaworska-Bieniek K, Narod SA, Lubinski J, Wojdacz TK, Jakubowska A.
    • Breast Cancer Res Treat. 2014 Dec;148(3):615-22. doi: 10.1007/s10549-014-3179-0. Epub 2014 Nov 7.
    • Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.
    • Loud JT.
    • Breast Cancer Res Treat. 2014 Dec;148(3):691-2. doi: 10.1007/s10549-014-3186-1.
    • Letter, Comment

    Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.

    Letter, Comment:

    Concerns about methods for determination of estrogens in body fluids.

    • Morphological and immunohistochemical pattern of tubo-ovarian dysplasia and serous tubal intraepithelial carcinoma.
    • Chene G, Cayre A, Raoelfils I, Lagarde N, Dauplat J, Penault-Llorca F.
    • Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:89-95. doi: 10.1016/j.ejogrb.2014.10.003. Epub 2014 Oct 14.
    • Distinct claudin expression characterizes BRCA1-related breast cancer.
    • Heerma van Voss MR, van Diest PJ, Smolders YH, Bart J, van der Wall E, van der Groep P.
    • Histopathology. 2014 Dec;65(6):814-27. doi: 10.1111/his.12490. Epub 2014 Aug 26.
    • Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
    • Toffoli S, Bar I, Abdel-Sater F, Delrée P, Hilbert P, Cavallin F, Moreau F, Van Criekinge W, Lacroix-Triki M, Campone M, Martin AL, Roché H, Machiels JP, Carrasco J, Canon JL.
    • Breast Cancer Res. 2014 Nov 22;16(6):466. doi: 10.1186/s13058-014-0466-y.
    • miRNA expression profiling of formalin-fixed paraffin-embedded (FFPE) hereditary breast tumors.
    • Tanić M, Yanowski K, Andrés E, Gómez-López G, Socorro MR, Pisano DG, Martinez-Delgado B, Benítez J.
    • Genom Data. 2014 Nov 22;3:75-9. doi: 10.1016/j.gdata.2014.11.008. eCollection 2015.
    • Clinical application of micronucleus test: a case-control study on the prediction of breast cancer risk/susceptibility.
    • Bolognesi C, Bruzzi P, Gismondi V, Volpi S, Viassolo V, Pedemonte S, Varesco L.
    • PLoS One. 2014 Nov 21;9(11):e112354. doi: 10.1371/journal.pone.0112354. eCollection 2014.
    • Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.
    • Danza K, De Summa S, Pilato B, Carella M, Palumbo O, Popescu O, Paradiso A, Pinto R, Tommasi S.
    • J Transl Med. 2014 Nov 19;12(1):319. doi: 10.1186/s12967-014-0319-6.
    • The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females.
    • Al-Moghrabi N, Nofel A, Al-Yousef N, Madkhali S, Bin Amer SM, Alaiya A, Shinwari Z, Al-Tweigeri T, Karakas B, Tulbah A, Aboussekhra A.
    • BMC Cancer. 2014 Nov 17;14:830. doi: 10.1186/1471-2407-14-830.
    • Clinicopathological features of young patients (<35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study.
    • Kataoka A, Tokunaga E, Masuda N, Shien T, Kawabata K, Miyashita M.
    • Breast Cancer. 2014 Nov;21(6):643-50. doi: 10.1007/s12282-013-0466-2. Epub 2013 Apr 16.
    • TGFβ Induces "BRCAness" and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes.
    • Liu L, Zhou W, Cheng CT, Ren X, Somlo G, Fong MY, Chin AR, Li H, Yu Y, Xu Y, O'Connor ST, O'Connor TR, Ann DK, Stark JM, Wang SE.
    • Mol Cancer Res. 2014 Nov;12(11):1597-609. doi: 10.1158/1541-7786.MCR-14-0201. Epub 2014 Aug 7.
    • Single Nucleotide Polymorphisms in Noncoding Regions of Rad51C Do Not Change the Risk of Unselected Breast Cancer but They Modulate the Level of Oxidative Stress and the DNA Damage Characteristics: A Case-Control Study.
    • Gresner P, Gromadzinska J, Jablonska E, Stepnik M, Zambrano Quispe O, Twardowska E, Wasowicz W.
    • PLoS One. 2014 Oct 24;9(10):e110696. doi: 10.1371/journal.pone.0110696. eCollection 2014.
    • Hereditary breast cancer: clinical, pathological and molecular characteristics.
    • Larsen MJ, Thomassen M, Gerdes AM, Kruse TA.
    • Breast Cancer (Auckl). 2014 Oct 15;8:145-55. doi: 10.4137/BCBCR.S18715. eCollection 2014.
    • Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199.
    • Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH.
    • J Clin Oncol. 2014 Oct 10;32(29):3275-83. doi: 10.1200/JCO.2013.54.1987. Epub 2014 Sep 8.

    Letter, Comment:

    Pathologic findings at risk-reducing surgery.

    Letter, Reply:

    Reply to m.j. Mourits et Al.

    • Retraction: Relation between HPV genotypes and BRCA mutation in familial breast cancer.
    • Rassi H, Mohammadian T, Salmanpor S, Gholami Roudmajani E.
    • J Microbiol Biotechnol. 2014 Oct 8. doi: 10.4014/jmb.1407.07011. [Epub ahead of print]
    • Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
    • Park JY, Singh TR, Nassar N, Zhang F, Freund M, Hanenberg H, Meetei AR, Andreassen PR.
    • Oncogene. 2014 Oct 2;33(40):4803-12. doi: 10.1038/onc.2013.421. Epub 2013 Oct 21.
    • Terminal duct lobular unit involution of the normal breast: implications for breast cancer etiology.
    • Figueroa JD, Pfeiffer RM, Patel DA, Linville L, Brinton LA, Gierach GL, Yang XR, Papathomas D, Visscher D, Mies C, Degnim AC, Anderson WF, Hewitt S, Khodr ZG, Clare SE, Storniolo AM, Sherman ME.
    • J Natl Cancer Inst. 2014 Oct 1;106(10). pii: dju286. doi: 10.1093/jnci/dju286. Print 2014 Oct.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: No pregnancy and risk of cancer

    • Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer.
    • Noori SF, Gangi A, Nelson ME, Choi M, Mirzadehgan P, Bonk AK, Mirocha J, Amersi F, Giuliano AE.
    • Ann Surg Oncol. 2014 Oct;21(10):3324-9. doi: 10.1245/s10434-014-3904-2. Epub 2014 Jul 22.
    • Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
    • Reyes MC, Arnold AG, Kauff ND, Levine DA, Soslow RA.
    • Mod Pathol. 2014 Oct;27(10):1405-11. doi: 10.1038/modpathol.2013.237. Epub 2014 Feb 28.
    • Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations.
    • Erturk E, Cecener G, Egeli U, Tunca B, Tezcan G, Gokgoz S, Tolunay S, Tasdelen I.
    • Mol Cell Biochem. 2014 Oct;395(1-2):77-88. doi: 10.1007/s11010-014-2113-4. Epub 2014 Jun 19.
    • BRCA1 pathway function in basal-like breast cancer cells.
    • Hill SJ, Clark AP, Silver DP, Livingston DM.
    • Mol Cell Biol. 2014 Oct;34(20):3828-42. doi: 10.1128/MCB.01646-13. Epub 2014 Aug 4.
    • Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment.
    • Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens JW, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter JP, Vreeswijk MP, Jager A, van Gent DC.
    • Clin Cancer Res. 2014 Sep 15;20(18):4816-26. doi: 10.1158/1078-0432.CCR-14-0571. Epub 2014 Jun 24.
    • Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.
    • Gruessner C, Gruessner A, Glaser K, AbuShahin N, Zhou Y, Laughren C, Wright H, Pinkerton S, Yi X, Stoffer J, Azodi M, Zheng W, Chambers SK.
    • Cancer Prev Res (Phila). 2014 Sep;7(9):896-905. doi: 10.1158/1940-6207.CAPR-13-0408. Epub 2014 Jun 20.
    • Reproductive and hormonal factors, family history, and breast cancer according to the hormonal receptor status.
    • Rosato V, Bosetti C, Negri E, Talamini R, Dal Maso L, Malvezzi M, Falcini F, Montella M, La Vecchia C.
    • Eur J Cancer Prev. 2014 Sep;23(5):412-7. doi: 10.1097/CEJ.0b013e3283639f7a.
    • A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    • Cass I, Walts AE, Barbuto D, Lester J, Karlan B.
    • Gynecol Oncol. 2014 Sep;134(3):492-7. doi: 10.1016/j.ygyno.2014.07.084. Epub 2014 Jul 12.
    • Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer.
    • Deb S, Johansson I, Byrne D, Nilsson C, Investigators k, Constable L, Fjällskog ML, Dobrovic A, Hedenfalk I, Fox SB.
    • Mod Pathol. 2014 Sep;27(9):1223-30. doi: 10.1038/modpathol.2013.231. Epub 2014 Jan 24.
    • Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers.
    • Gevensleben H, Bossung V, Meindl A, Wappenschmidt B, de Gregorio N, Osorio A, Romero A, Buettner R, Markiefka B, Schmutzler RK.
    • Virchows Arch. 2014 Sep;465(3):365-9. doi: 10.1007/s00428-014-1619-1. Epub 2014 Jul 4.
    • Letter
    • Biology of breast cancer in young women.
    • Azim HA, Partridge AH.
    • Breast Cancer Res. 2014 Aug 27;16(4):427. doi: 10.1186/s13058-014-0427-5.
    • Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study.
    • Gierach GL, Li H, Loud JT, Greene MH, Chow CK, Lan L, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Olopade OI, Gail MH, Giger ML.
    • Breast Cancer Res. 2014;16(4):424. doi: 10.1186/PREACCEPT-1744229618121391. Epub 2014 Aug 23.
    • Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.
    • Prat A, Cruz C, Hoadley KA, Díez O, Perou CM, Balmaña J.
    • Breast Cancer Res Treat. 2014 Aug;147(1):185-91. doi: 10.1007/s10549-014-3056-x. Epub 2014 Jul 22.
    • VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer.
    • Castilla MÁ, López-García MÁ, Atienza MR, Rosa-Rosa JM, Díaz-Martín J, Pecero ML, Vieites B, Romero-Pérez L, Benítez J, Calcabrini A, Palacios J.
    • Endocr Relat Cancer. 2014 Aug;21(4):587-99. doi: 10.1530/ERC-13-0485. Epub 2014 Jun 2.
    • BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    • Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.
    • Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.
    • MicroRNAs Discriminate Familial from Sporadic Non-BRCA1/2 Breast Carcinoma Arising in Patients ≤35 Years.
    • Bastos EP, Brentani H, Pasini FS, Silva AR, Torres CH, Puga RD, Olivieri EH, Piovezani AR, Pereira CA, Machado-Lima A, Carraro DM, Brentani MM.
    • PLoS One. 2014 Jul 9;9(7):e101656. doi: 10.1371/journal.pone.0101656. eCollection 2014.
    • A small organ takes center stage: selected topics in fallopian tube pathology.
    • Rutgers JK, Lawrence WD.
    • Int J Gynecol Pathol. 2014 Jul;33(4):385-92. doi: 10.1097/PGP.0000000000000143.
    • Displaced Granulosa Cells Within the Ovarian Stroma in a BRCA1 Mutation Carrier.
    • Chui MH, Chapman WB, Clarke BA.
    • Int J Gynecol Pathol. 2014 Jul;33(4):423-4. doi: 10.1097/PGP.0b013e3182a3cd2c.
    • Letter, Comment

    Case report:

    Displaced granulosa cells in the fallopian tube mistaken for metastatic granulosa cell tumor.

    • Family history of cancer associated with breast tumor clinicopathological features.
    • Ricks LJ, Ewing A, Thompson N, Harrison B, Wilson B, Richardson F, Carter-Nolan P, Spencer C, Laiyemo A, Williams C.
    • J Community Genet. 2014 Jul;5(3):233-40. doi: 10.1007/s12687-013-0180-y. Epub 2014 Jan 15.
    • A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival.
    • Anjum S, Fourkala EO, Zikan M, Wong A, Gentry-Maharaj A, Jones A, Hardy R, Cibula D, Kuh D, Jacobs IJ, Teschendorff AE, Menon U, Widschwendter M.
    • Genome Med. 2014 Jun 27;6(6):47. doi: 10.1186/gm567. eCollection 2014.

    Press: Prospects for blood test to predict breast cancer risk. (PHG Foundation)

    • Clinicopathological features and prognostic factors of young breast cancers in Eastern Guangdong of China.
    • Wei JT, Huang WH, Du CW, Qiu SQ, Wei XL, Liu J, Zhang GJ.
    • Sci Rep. 2014 Jun 19;4:5360. doi: 10.1038/srep05360.
    • Genomic Aberrations of BRCA1-Mutated Fallopian Tube Carcinomas.
    • Hunter SM, Ryland GL, Moss P; kConFab Investigators, Gorringe KL, Campbell IG.
    • Am J Pathol. 2014 Jun;184(6):1871-6. doi: 10.1016/j.ajpath.2014.02.013. Epub 2014 Apr 13.
    • Early Detection of High-grade Tubal Serous Carcinoma in Women at Low Risk for Hereditary Breast and Ovarian Cancer Syndrome by Systematic Examination of Fallopian Tubes Incidentally Removed During Benign Surgery.
    • Rabban JT, Garg K, Crawford B, Chen LM, Zaloudek CJ.
    • Am J Surg Pathol. 2014 Jun;38(6):729-42. doi: 10.1097/PAS.0000000000000199.
    • Lymphocyte Telomere Length Is Long in BRCA1 and BRCA2 Mutation Carriers Regardless of Cancer-Affected Status.
    • Pooley KA, McGuffog L, Barrowdale D, Frost D, Ellis SD, Fineberg E, Platte R, Izatt L, Adlard J, Bardwell J, Brewer C, Cole T, Cook J, Davidson R, Donaldson A, Dorkins H, Douglas F, Eason J, Houghton C, Kennedy MJ, McCann E, Miedzybrodzka Z, Murray A, Porteous ME, Rogers MT, Side LE, Tischkowitz M, Walker L, Hodgson S, Eccles DM, Morrison PJ, Evans DG, Eeles RA, Antoniou AC, Easton DF, Dunning AM; EMBRACE;.
    • Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1018-24. doi: 10.1158/1055-9965.EPI-13-0635-T. Epub 2014 Mar 18.
    • Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
    • Chen Y, Bancroft E, Ashley S, Arden-Jones A, Thomas S, Shanley S, Saya S; Carrier Clinic Collaborators, Wakeling E, Eeles R.
    • Fam Cancer. 2014 Jun;13(2):197-203. doi: 10.1007/s10689-013-9697-9.
    • Characteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry.
    • Yu JH, Lee JW, Son BH, Kim SW, Park SK, Lee MH, Kim LS, Noh WC, Kim EK, Yoon DS, Lee J, Jung JH, Jung SS, Gong G, Ahn SH.
    • J Breast Cancer. 2014 Jun;17(2):129-35. doi: 10.4048/jbc.2014.17.2.129. Epub 2014 Jun 27.
    • Genome instability in blood cells of a BRCA1+ breast cancer family.
    • Xiao F, Kim YC, Snyder C, Wen H, Chen PX, Luo J, Becirovic D, Downs B, Cowan KH, Lynch H, Wang SM.
    • BMC Cancer. 2014 May 19;14:342. doi: 10.1186/1471-2407-14-342.
    • Systemic treatment strategies for triple-negative breast cancer.
    • Yadav BS, Sharma SC, Chanana P, Jhamb S.
    • World J Clin Oncol. 2014 May 10;5(2):125-33. doi: 10.5306/wjco.v5.i2.125.
    • Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk.
    • Anton A, Schott S, Kaip G, Rath M, Heil J, Aulmann S, Sinn HP.
    • Arch Gynecol Obstet. 2014 May;289(5):1079-85. doi: 10.1007/s00404-013-3062-y. Epub 2013 Nov 7.
    • Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    • Aloraifi F, Alshehhi M, McDevitt T, Cody N, Meany M, O'Doherty A, Quinn CM, Green AJ, Bracken A, Geraghty JG.
    • Eur J Surg Oncol. 2015 May;41(5):641-6. doi: 10.1016/j.ejso.2015.01.021. Epub 2015 Feb 17.
    • Risk factors for ovarian cancers with and without microsatellite instability.
    • Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Sun P, Narod SA, Schildkraut J.
    • Int J Gynecol Cancer. 2014 May;24(4):664-9. doi: 10.1097/IGC.0000000000000134.
    • Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    • Staff S, Tolonen T, Laasanen SL, Mecklin JP, Isola J, Mäenpää J.
    • Int J Gynecol Pathol. 2014 May;33(3):309-16. doi: 10.1097/PGP.0b013e31829c673b.
    • BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis.
    • Tang MK, Kwong A, Tam KF, Cheung AN, Ngan HY, Xia W, Wong A.
    • Cancer Lett. 2014 Apr 28;346(1):139-47. doi: 10.1016/j.canlet.2013.12.026. Epub 2013 Dec 28.
    • Comparison of breast cancers diagnosed in screening patients in their 40s with and without family history of breast cancer in a community outpatient facility.
    • Destounis SV, Arieno AL, Morgan RC, Cavanaugh D, Seifert PJ, Murphy PF, Somerville PA.
    • AJR Am J Roentgenol. 2014 Apr;202(4):928-32. doi: 10.2214/AJR.13.11194.
    • SUMOylation proteins in breast cancer.
    • Alshareeda AT, Negm OH, Green AR, Nolan C, Tighe P, Albarakati N, Sultana R, Madhusudan S, Ellis IO, Rakha EA.
    • Breast Cancer Res Treat. 2014 Apr;144(3):519-30. doi: 10.1007/s10549-014-2897-7. Epub 2014 Mar 1.
    • Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.
    • van Verschuer VM, Heemskerk-Gerritsen BA, van Deurzen CH, Obdeijn IM, Tilanus-Linthorst MM, Verhoef C, Schmidt MK, Koppert LB, Hooning MJ, Seynaeve C.
    • Cancer Biol Ther. 2014 Apr;15(4):371-9. doi: 10.4161/cbt.27628. Epub 2014 Jan 14.
    • Hereditary risk evaluation for borderline ovarian tumors based on immunohistochemistry.
    • Park JM, Kim MK.
    • J Menopausal Med. 2014 Apr;20(1):14-20. doi: 10.6118/jmm.2014.20.1.14. Epub 2014 Apr 28.
    • Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS.
    • Saito M, Matsuzaki M, Sakuma T, Katagata N, Watanabe F, Yamaguchi Y, Schetter AJ, Takenoshita S, Nomizu T.
    • Breast Cancer. 2014 Mar;21(2):140-5. doi: 10.1007/s12282-012-0389-3. Epub 2012 Aug 9.
    • BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.
    • Burgess M, Puhalla S.
    • Front Oncol. 2014 Feb 27;4:19. eCollection 2014.
    • Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.
    • De Summa S, Pinto R, Pilato B, Sambiasi D, Porcelli L, Guida G, Mattioli E, Paradiso A, Merla G, Micale L, De Nittis P, Tommasi S.
    • Cell Death Dis. 2014 Feb 20;5:e1076. doi: 10.1038/cddis.2014.30.
    • Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis.
    • Li HX, Lu ZH, Shen K, Cheng WJ, Malpica A, Zhang J, Wei JJ, Zhang ZH, Liu J.
    • Int J Clin Exp Pathol. 2014 Feb 15;7(3):848-57. eCollection 2014.
    • Regulation of DNA methyltransferase 1 transcription in BRCA1-mutated breast cancer: a novel crosstalk between E2F1 motif hypermethylation and loss of histone H3 lysine 9 acetylation.
    • Li D, Bi FF, Cao JM, Cao C, Liu B, Yang Q.
    • Mol Cancer. 2014 Feb 6;13:26. doi: 10.1186/1476-4598-13-26.
    • Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube.
    • Dietl J.
    • Arch Gynecol Obstet. 2014 Feb;289(2):241-6. doi: 10.1007/s00404-013-3041-3. Epub 2013 Oct 8.
    • Review
  1. s
    • Clinical significance of CYLD downregulation in breast cancer.
    • Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M, Murakami K, Yamashita S, Yamamoto Y, Li JD, Iwase H, Ando Y.
    • Breast Cancer Res Treat. 2014 Feb;143(3):447-57. doi: 10.1007/s10549-013-2824-3. Epub 2014 Jan 8.
    • Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.
    • Loud JT, Gierach GL, Veenstra TD, Falk RT, Nichols K, Guttmann A, Xu X, Greene MH, Gail MH.
    • Breast Cancer Res Treat. 2014 Feb;143(3):517-29. doi: 10.1007/s10549-013-2821-6. Epub 2014 Jan 18.

    Letter, Comment:

    Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers.

    Letter, Comment:

    Concerns about methods for determination of estrogens in body fluids.

    • Triple-negative breast cancer: molecular subtypes and targeted therapy.
    • Hirshfield KM, Ganesan S.
    • Curr Opin Obstet Gynecol. 2014 Feb;26(1):34-40. doi: 10.1097/GCO.0000000000000038.
    • Review
    • Differences in DNA methylation by extent of breast cancer family history in unaffected women.
    • Delgado-Cruzata L, Wu HC, Liao Y, Santella RM, Terry MB.
    • Epigenetics. 2014 Feb;9(2):243-8. doi: 10.4161/epi.26880. Epub 2013 Oct 29.
    • BRCA1/2 mutations and FMR1 alleles are randomly distributed: a case control study.
    • Dagan E, Cohen Y, Mory A, Adir V, Borochowitz Z, Raanani H, Kurolap A, Melikhan-Revzin S, Meirow D, Gershoni-Baruch R.
    • Eur J Hum Genet. 2014 Feb;22(2):277-9. doi: 10.1038/ejhg.2013.281. Epub 2013 Nov 27.
    • The FMR1 CGG repeat test is not a candidate prescreening tool for identifying women with a high probability of being carriers of BRCA mutations.
    • Ricci MT, Pennese L, Gismondi V, Perfumo C, Grasso M, Gennaro E, Bruzzi P, Varesco L.
    • Eur J Hum Genet. 2014 Feb;22(2):280-2. doi: 10.1038/ejhg.2013.193. Epub 2013 Sep 25.

    Comment:

    Do BRCA1/2 mutations and low FMR1 alleles interact or not?

    • The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
    • Reade CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE.
    • J Obstet Gynaecol Can. 2014 Feb;36(2):133-40.
    • Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.
    • Suspitsin EN, Yanus GA, Sokolenko AP, Yatsuk OS, Zaitseva OA, Bessonov AA, Ivantsov AO, Heinstein VA, Klimashevskiy VF, Togo AV, Imyanitov EN.
    • Med Oncol. 2014 Feb;31(2):828. doi: 10.1007/s12032-013-0828-9. Epub 2014 Jan 12.
    • Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
    • De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, Seoane J, Reis-Filho JS.
    • Mol Oncol. 2014 Feb;8(1):150-8. doi: 10.1016/j.molonc.2013.10.006. Epub 2013 Oct 31.
    • RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.
    • Larsen MJ, Thomassen M, Tan Q, Lænkholm AV, Bak M, Sørensen KP, Andersen MK, Kruse TA, Gerdes AM.
    • BMC Med Genomics. 2014 Jan 31;7(1):9. doi: 10.1186/1755-8794-7-9.
    • Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status.
    • Killick E, Tymrakiewicz M, Cieza-Borrella C, Smith P, Thompson DJ, Pooley KA, Easton DF, Bancroft E, Page E, Leongamornlert D; IMPACT collaborators, Kote-Jarai Z, Eeles RA.
    • PLoS One. 2014 Jan 29;9(1):e86659. doi: 10.1371/journal.pone.0086659. eCollection 2014.
    • Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.
    • Sama AR, Schilder RJ.
    • Int J Womens Health. 2014 Jan 28;6:149-57. doi: 10.2147/IJWH.S40889. eCollection 2014.
    • BRCA and Early Events in the Development of Serous Ovarian Cancer.
    • George SH, Shaw P.
    • Front Oncol. 2014 Jan 23;4:5. doi: 10.3389/fonc.2014.00005. eCollection 2014.
    • Integrated analysis of germline and somatic variants in ovarian cancer.
    • Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, Zhang Q, Koboldt DC, Xie M, Kandoth C, McMichael JF, Wyczalkowski MA, Larson DE, Schmidt HK, Miller CA, Fulton RS, Spellman PT, Mardis ER, Druley TE, Graubert TA, Goodfellow PJ, Raphael BJ, Wilson RK, Ding L.
    • Nat Commun. 2014 Jan 22;5:3156. doi: 10.1038/ncomms4156.
    • Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma.
    • Gruessner C, Gruessner A, Glaser K, Abushahin N, Laughren C, Zheng W, Chambers SK.
    • Am J Cancer Res. 2014 Jan 15;4(1):61-72. eCollection 2014.
    • Triple-negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome.
    • Sullivan HC, Oprea-Ilies G, Adams AL, Page AJ, Kim S, Wang J, Cohen C.
    • Appl Immunohistochem Mol Morphol. 2014 Jan;22(1):17-23. doi: 10.1097/PAI.0b013e318281148e.
    • Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.
    • Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J, Segerer SE.
    • Arch Gynecol Obstet. 2014 Jan;289(1):141-7. doi: 10.1007/s00404-013-2922-9. Epub 2013 Jul 5.
    • Breast cancer subtypes and previously established genetic risk factors: a bayesian approach.
    • O'Brien KM, Cole SR, Engel LS, Bensen JT, Poole C, Herring AH, Millikan RC.
    • Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):84-97. doi: 10.1158/1055-9965.EPI-13-0463. Epub 2013 Oct 31.
    • BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.
    • Foulkes W.
    • Clin Genet. 2014 Jan;85(1):1-4. doi: 10.1111/cge.12291. Epub 2013 Oct 25.
    • Editorial / Commentary
    • The impact of bilateral salpingo-oophorectomy on breast MRI background parenchymal enhancement and fibroglandular tissue.
    • Price ER, Brooks JD, Watson EJ, Brennan SB, Comen EA, Morris EA.
    • Eur Radiol. 2014 Jan;24(1):162-8. doi: 10.1007/s00330-013-2993-9. Epub 2013 Aug 28.
    • Lobulitis in nonneoplastic breast tissue from breast cancer patients: association with phenotypes that are common in hereditary breast cancer.
    • Gulbahce HE, Vanderwerf S, Blair C, Sweeney C.
    • Hum Pathol. 2014 Jan;45(1):78-84. doi: 10.1016/j.humpath.2013.08.008. Epub 2013 Oct 21.
    • Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.
    • Hirasawa A, Masuda K, Akahane T, Ueki A, Yokota M, Tsuruta T, Nomura H, Kataoka F, Tominaga E, Banno K, Makita K, Susumu N, Sugano K, Kosaki K, Kameyama K, Aoki D.
    • Jpn J Clin Oncol. 2014 Jan;44(1):49-56. doi: 10.1093/jjco/hyt171. Epub 2013 Nov 11.
    • Influence of estrogen and variations at the BRCA1 promoter region on transcription and translation.
    • Fernandes LR, Costa EC, Vargas FR, Moreira MA.
    • Mol Biol Rep. 2014 Jan;41(1):489-95. doi: 10.1007/s11033-013-2884-9. Epub 2013 Dec 1.
    • Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer.
    • Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J, Miklasevics E.
    • Oncol Lett. 2014 Jan;7(1):278-284. Epub 2013 Nov 14.
    • [Morphologically qnd immunohistochemically based screening criteria for selection of patients with possible mutation of BRCA1 gene in primary ovarian cancer].
    • Popovska S, Ivanov I, Dineva T, Jordanov A, Kovacheva K, Kamburova Z, Tomov S, Ivanova V, Boneva I, Mateva S.
    • Akush Ginekol (Sofiia). 2014;53(4):21-8.
    • [Article in Bulgarian]
    • BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.
    • Li D, Chen NN, Cao JM, Sun WP, Zhou YM, Li CY, Wang XX.
    • Cell Cycle. 2014;13(16):2564-71. doi: 10.4161/15384101.2015.942208.
    • Hormone responsive breast cancer and BRCA1 mutation: mechanism, regulation and iron-mediated effects.
    • Zghair AN, Sharma R, Sharma AK.
    • Curr Pharm Biotechnol. 2014;15(12):1113-24.
    • Review
    • Network-based analysis of omics with multi-objective optimization.
    • Mosca E, Milanesi L.
    • Mol Biosyst. 2013 Dec 29;9(12):2971-80. doi: 10.1039/c3mb70327d. Epub 2013 Oct 14.
    • Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas.
    • Pécuchet N, Popova T, Manié E, Lucchesi C, Battistella A, Vincent-Salomon A, Caux-Moncoutier V, Bollet M, Sigal-Zafrani B, Sastre-Garau X, Stoppa-Lyonnet D, Stern MH.
    • Int J Cancer. 2013 Dec 15;133(12):2834-2842. doi: 10.1002/ijc.28315. Epub 2013 Jul 10.
    • Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.
    • Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R.
    • Cancer Cell. 2013 Dec 9;24(6):751-65. doi: 10.1016/j.ccr.2013.10.013.

    Research news:

    Ovarian cancer: A better mimic.

    • Tackling the diversity of triple-negative breast cancer.
    • Turner NC, Reis-Filho JS.
    • Clin Cancer Res. 2013 Dec 1;19(23):6380-8. doi: 10.1158/1078-0432.CCR-13-0915.
    • Clinical implications of using molecular diagnostics for ovarian cancers.
    • Kohn EC, Romano S, Lee JM.
    • Ann Oncol. 2013 Dec;24 Suppl 10:x22-26. doi: 10.1093/annonc/mdt464.
    • Explaining variance in the cumulus mammographic measures that predict breast cancer risk: a twins and sisters study.
    • Nguyen TL, Schmidt DF, Makalic E, Dite GS, Stone J, Apicella C, Bui M, Macinnis RJ, Odefrey F, Cawson JN, Treloar SA, Southey MC, Giles GG, Hopper JL.
    • Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2395-403. doi: 10.1158/1055-9965.EPI-13-0481. Epub 2013 Oct 15.
    • Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer.
    • Crum CP, Herfs M, Ning G, Bijron JG, Howitt BE, Jimenez CA, Hanamornroongruang S, McKeon FD, Xian W.
    • J Pathol. 2013 Dec;231(4):402-12. doi: 10.1002/path.4263.
    • MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
    • Ren J, Jin F, Yu Z, Zhao L, Wang L, Bai X, Zhao H, Yao W, Mi X, Wang E, Olopade OI, Wei M.
    • Tumour Biol. 2013 Dec;34(6):3945-58. doi: 10.1007/s13277-013-0983-9. Epub 2013 Jul 17.
    • MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours.
    • Tanic M, Andrés E, M Rodriguez-Pinilla S, Marquez-Rodas I, Cebollero-Presmanes M, Fernandez V, Osorio A, Benítez J, Martinez-Delgado B.
    • Br J Cancer. 2013 Nov 12;109(10):2724-34. doi: 10.1038/bjc.2013.612. Epub 2013 Oct 8.
    • Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.
    • PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.
    • Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules.
    • Isfoss BL, Holmqvist B, Jernström H, Alm P, Olsson H.
    • BMC Clin Pathol. 2013 Nov 4;13(1):28. doi: 10.1186/1472-6890-13-28.
    • The role of the fallopian tube in the origin of ovarian cancer.
    • Erickson BK, Conner MG, Landen CN Jr.
    • Am J Obstet Gynecol. 2013 Nov;209(5):409-14. doi: 10.1016/j.ajog.2013.04.019. Epub 2013 Apr 10.

    Letter, Comment:

    Risk-reducing salpingectomy as a new and safe strategy to prevent ovarian cancer.

    Letter, Reply:

    Reply: To PMID 23583217.

    • Biology of hereditary breast and ovarian cancers.
    • Tommasi S.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii7. doi: 10.1093/annonc/mdt309.
    • Breast cancer risk in BRCA1 mutation carriers: insight from mouse models.
    • Barcellos-Hoff MH, Kleinberg DL.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii8-viii12. doi: 10.1093/annonc/mdt305.
    • Coming into focus: the nonovarian origins of ovarian cancer.
    • Dubeau L, Drapkin R.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii28-viii35. doi: 10.1093/annonc/mdt308.
    • Male breast cancer: genetics, epigenetics, and ethical aspects.
    • Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, Gulino M, Frati P, Ottini L.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii75-viii82. doi: 10.1093/annonc/mdt316.
    • Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
    • Vilasco M, Communal L, Hugon-Rodin J, Penault-Llorca F, Mourra N, Wu Z, Forgez P, Gompel A; BRACAPS.
    • Breast Cancer Res Treat. 2013 Nov;142(2):283-96. doi: 10.1007/s10549-013-2722-8. Epub 2013 Oct 29.
    • MicroRNA signatures in hereditary breast cancer.
    • Murria Estal R, Palanca Suela S, de Juan Jiménez I, Egoavil Rojas C, García-Casado Z, Juan Fita MJ, Sánchez Heras AB, Segura Huerta A, Chirivella González I, Sánchez-Izquierdo D, Llop García M, Barragán González E, Bolufer Gilabert P.
    • Breast Cancer Res Treat. 2013 Nov;142(1):19-30. doi: 10.1007/s10549-013-2723-7. Epub 2013 Oct 16.
    • Increased Proliferative Background in Healthy Women with BRCA1/2 Haploinsufficiency Is Associated with High Risk for Breast Cancer.
    • Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, Peretz T.
    • Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2110-5. doi: 10.1158/1055-9965.EPI-13-0193. Epub 2013 Aug 21.
    • BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.
    • Buckley NE, Nic An Tsaoir CB, Blayney JK, Oram LC, Crawford NT, D'Costa ZC, Quinn JE, Kennedy RD, Harkin DP, Mullan PB.
    • Nucleic Acids Res. 2013 Oct 1;41(18):8601-14. doi: 10.1093/nar/gkt626. Epub 2013 Jul 17.
    • The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy.
    • Markowska J, Bar J, Mądry R, Słomska I, Mardas M, Grabowski JP.
    • Arch Gynecol Obstet. 2013 Oct;288(4):839-44. doi: 10.1007/s00404-013-2825-9. Epub 2013 Apr 4.
    • Pyrimidine base damage is increased in women with BRCA mutations.
    • Budzinski EE, Patrzyc HB, Dawidzik JB, Freund HG, Frederick P, Godoy HE, Voian NC, Odunsi K, Box HC.
    • Cancer Lett. 2013 Sep 28;338(2):267-70. doi: 10.1016/j.canlet.2013.04.001. Epub 2013 Apr 11.
    • Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade.
    • Martinez-Delgado B, Gallardo M, Tanic M, Yanowsky K, Inglada-Perez L, Barroso A, Rodriguez-Pinilla M, Cañamero M, Blasco MA, Benitez J.
    • Breast Cancer Res Treat. 2013 Sep;141(2):231-42. doi: 10.1007/s10549-013-2696-6. Epub 2013 Sep 15.
    • Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients.
    • Pedersen BS, Konstantinopoulos PA, Spillman MA, De S.
    • Genes Chromosomes Cancer. 2013 Sep;52(9):794-801. doi: 10.1002/gcc.22075. Epub 2013 May 28.
    • Cytogenetic finding of breast cancer cases and in their first-degree relatives.
    • Celik DA, Koşar PA, Ozçelik N, Eroğlu E.
    • J Breast Cancer. 2013 Sep;16(3):285-90. doi: 10.4048/jbc.2013.16.3.285. Epub 2013 Sep 30.
    • Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation.
    • Noh JM, Han BK, Choi DH, Rhee SJ, Cho EY, Huh SJ, Park W, Park H, Nam SJ, Lee JE, Kil WH.
    • J Breast Cancer. 2013 Sep;16(3):308-14. doi: 10.4048/jbc.2013.16.3.308. Epub 2013 Sep 30.
    • Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    • Yi YW, Kang HJ, Kim HJ, Hwang JS, Wang A, Bae
    • Mol Carcinog. 2013 Sep;52(9):667-75. doi: 10.1002/mc.21905. Epub 2012 Apr 4.
    • BRCA1 and p53 regulate critical prostate cancer pathways.
    • De Luca P, Moiola CP, Zalazar F, Gardner K, Vazquez ES, De Siervi A.
    • Prostate Cancer Prostatic Dis. 2013 Sep;16(3):233-8. doi: 10.1038/pcan.2013.12. Epub 2013 May 14.
    • Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
    • Bijron JG, Seldenrijk CA, Zweemer RP, Lange JG, Verheijen RH, van Diest PJ.
    • Am J Surg Pathol. 2013 Aug;37(8):1123-30. doi: 10.1097/PAS.0b013e318282da7f.
    • Case report

    Letter, Comment:

    Fallopian tube intraluminal tumor spread.

    Letter, Comment:

    Serous carcinogenesis: a classic causality dilemma or which came first... ?

    • Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype.
    • Senkus E, Szade J, Pieczyńska B, Żaczek A, Brożek I, Radecka B, Kowalczyk A, Wełnicka-Jaśkiewicz M, Jassem J.
    • Breast. 2013 Aug;22(4):425-30. doi: 10.1016/j.breast.2013.04.005. Epub 2013 May 1.
    • Autophagy Opposes p53-Mediated Tumor Barrier to Facilitate Tumorigenesis in a Model of PALB2-Associated Hereditary Breast Cancer.
    • Huo Y, Cai H, Teplova I, Bowman-Colin C, Chen G, Price S, Barnard N, Ganesan S, Karantza V, White E, Xia B.
    • Cancer Discov. 2013 Aug;3(8):894-907. doi: 10.1158/2159-8290.CD-13-0011. Epub 2013 May 6.
    • Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer.
    • Danza K, Pilato B, Lacalamita R, Addati T, Giotta F, Bruno A, Paradiso A, Tommasi S.
    • Eur J Hum Genet. 2013 Aug;21(8):824-30. doi: 10.1038/ejhg.2012.273. Epub 2012 Dec 12.
    • The complex genetic landscape of familial breast cancer.
    • Melchor L, Benítez J.
    • Hum Genet. 2013 Aug;132(8):845-63. doi: 10.1007/s00439-013-1299-y. Epub 2013 Apr 5.
    • Review
    • Tuberin and p27 expression in breast cancer patients with or without BRCA germline mutations.
    • Dressler AC, Hudelist G, Fink-Retter A, Gschwantler-Kaulich D, Pfeiler G, Rosner M, Hengstschläger M, Singer CF.
    • J Cancer Res Clin Oncol. 2013 Aug;139(8):1349-55. doi: 10.1007/s00432-013-1443-z. Epub 2013 May 21.
    • Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations.
    • Tulchin N, Ornstein L, Dikman S, Strauchen J, Jaffer S, Nagi C, Bleiweiss I, Kornreich R, Edelmann L, Brown K, Bodian C, Nair VD, Chambon M, Woods NT, Monteiro AN.
    • Cancer Cell Int. 2013 Jul 15;13(1):70. doi: 10.1186/1475-2867-13-70.
    • Tumour morphology predicts PALB2 germline mutation status.
    • Teo ZL, Provenzano E, Dite GS, Park DJ, Apicella C, Sawyer SD, James PA, Mitchell G, Trainer AH, Lindeman GJ, Shackleton K, Cicciarelli L; kConFab, Buys SS, Andrulis IL, Mulligan AM, Glendon G, John EM, Terry MB, Daly M, Odefrey FA, Nguyen-Dumont T, Giles GG, Dowty JG, Winship I, Goldgar DE, Hopper JL, Southey MC.
    • Br J Cancer. 2013 Jul 9;109(1):154-63. doi: 10.1038/bjc.2013.295. Epub 2013 Jun 20.
    • Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    • George J, Alsop K, Etemadmoghadam D, Hondow H, Mikeska T, Dobrovic A, deFazio A; Australian Ovarian Cancer Study Group, Smyth GK, Levine DA, Mitchell G, Bowtell DD.
    • Clin Cancer Res. 2013 Jul 1;19(13):3474-84. doi: 10.1158/1078-0432.CCR-13-0066. Epub 2013 Apr 30.

    Research news:

    Genomic signatures of BRCA1 but not BRCA2 associated high-grade serous carcinoma resemble basal-like breast cancer.

    • Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
    • Tryggvadottir L, Olafsdottir EJ, Olafsdottir GH, Sigurdsson H, Johannsson OT, Bjorgvinsson E, Alexiusdottir K, Stefansson OA, Agnarsson BA, Narod SA, Eyfjord JE, Jonasson JG.
    • Breast Cancer Res Treat. 2013 Jul;140(2):375-84. doi: 10.1007/s10549-013-2637-4. Epub 2013 Jul 16.
    • Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    • Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.
    • Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.
    • Relationship between family history of breast cancer and clinicopathological features in moroccan patients.
    • Tazzite A, Jouhadi H, Saiss K, Benider A, Nadifi S.
    • Ethiop J Health Sci. 2013 Jul;23(2):150-7.
    • Ovarian surface epithelium as a source of ovarian cancers: Unwarranted speculation or evidence-based hypothesis?
    • Auersperg N.
    • Gynecol Oncol. 2013 Jul;130(1):246-51. doi: 10.1016/j.ygyno.2013.03.021. Epub 2013 Apr 2.
    • Review
    • Risk factors for ovarian cancers with and without microsatellite instability.
    • Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J.
    • Int J Gynecol Cancer. 2013 Jul;23(6):1010-5. doi: 10.1097/IGC.0b013e31829a5527.

    Retraction:

    Retraction.

    • BRCA1-Dependent Translational Regulation in Breast Cancer Cells.
    • Dacheux E, Vincent A, Nazaret N, Combet C, Wierinckx A, Mazoyer S, Diaz JJ, Lachuer J, Venezia ND.
    • PLoS One. 2013 Jun 21;8(6):e67313. Print 2013.
    • Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions.
    • Chene G, Tchirkov A, Pierre-Eymard E, Dauplat J, Raoelfils I, Cayre A, Watkin E, Vago P, Penault-Llorca F.
    • Clin Cancer Res. 2013 Jun 1;19(11):2873-82. doi: 10.1158/1078-0432.CCR-12-3947. Epub 2013 Apr 15.

    Letter, Comment:

    Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions--letter.

    Letter, Reply:

    Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions--response.

    • Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
    • Alshareeda AT, Negm OH, Albarakati N, Green AR, Nolan C, Sultana R, Madhusudan S, Benhasouna A, Tighe P, Ellis IO, Rakha EA.
    • Breast Cancer Res Treat. 2013 Jun;139(2):301-10. doi: 10.1007/s10549-013-2542-x. Epub 2013 Apr 28.
    • Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.
    • Schouten PC, van Dyk E, Braaf LM, Mulder L, Lips EH, de Ronde JJ, Holtman L, Wesseling J, Hauptmann M, Wessels LF, Linn SC, Nederlof PM.
    • Breast Cancer Res Treat. 2013 Jun;139(2):317-27. doi: 10.1007/s10549-013-2558-2. Epub 2013 May 14.
    • Different methylation and microRNA expression pattern in male and female familial breast cancer.
    • Pinto R, Pilato B, Ottini L, Lambo R, Simone G, Paradiso A, Tommasi S.
    • J Cell Physiol. 2013 Jun;228(6):1264-9. doi: 10.1002/jcp.24281.
    • Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.
    • Alvarez C, Tapia T, Cornejo V, Fernandez W, Muñoz A, Camus M, Alvarez M, Devoto L, Carvallo P.
    • Mol Carcinog. 2013 Jun;52(6):475-87. doi: 10.1002/mc.21881. Epub 2012 Feb 7.
    • Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67.
    • Hassanein M, Huiart L, Bourdon V, Rabayrol L, Geneix J, Nogues C, Peyrat JP, Gesta P, Meynard P, Dreyfus H, Petrot D, Lidereau R, Noguchi T, Eisinger F, Extra JM, Viens P, Jacquemier J, Sobol H.
    • Pathobiology. [2013 Jun;]80(5):219-27. doi: 10.1159/000339432. Epub 2013 Apr 23.
    • BRCA1 mutations and luminal-basal transformation.
    • Ng T, Irshad S, Stebbing J.
    • Oncogene. 2013 May 30;32(22):2712-4. doi: 10.1038/onc.2012.379. Epub 2012 Aug 27.
    • Comment

    Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.

    • Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.
    • Bai F, Smith MD, Chan HL, Pei XH.
    • Oncogene. 2013 May 30;32(22):2715-25. doi: 10.1038/onc.2012.293. Epub 2012 Jul 9.

    Comment:

    BRCA1 mutations and luminal-basal transformation.

    • Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
    • Larsen MJ, Kruse TA, Tan Q, Lænkholm AV, Bak M, Lykkesfeldt AE, Sørensen KP, Hansen TV, Ejlertsen B, Gerdes AM, Thomassen M.
    • PLoS One. 2013 May 21;8(5):e64268. doi: 10.1371/journal.pone.0064268. Print 2013.
    • Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
    • Bowman-Colin C, Xia B, Bunting S, Klijn C, Drost R, Bouwman P, Fineman L, Chen X, Culhane AC, Cai H, Rodig SJ, Bronson RT, Jonkers J, Nussenzweig A, Kanellopoulou C, Livingston DM.
    • Proc Natl Acad Sci U S A. 2013 May 21;110(21):8632-7. doi: 10.1073/pnas.1305362110. Epub 2013 May 8.
    • Male breast cancer according to tumor subtype and race : A population-based study.
    • Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH.
    • Cancer. 2013 May 1;119(9):1611-7. doi: 10.1002/cncr.27905. Epub 2013 Jan 22.
    • TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.
    • Shan J, Dsouza SP, Bakhru S, Al-Azwani EK, Ascierto ML, Sastry KS, Bedri S, Kizhakayil D, Aigha II, Malek J, Al-Bozom I, Gehani S, Furtado S, Mathiowitz E, Wang E, Marincola FM, Chouchane L.
    • Cancer Res. 2013 May 1;73(9):2840-9. doi: 10.1158/0008-5472.CAN-12-4313. Epub 2013 Feb 27.
    • Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.
    • Wark L, Novak D, Sabbaghian N, Amrein L, Jangamreddy JR, Cheang M, Pouchet C, Aloyz R, Foulkes WD, Mai S, Tischkowitz M.
    • Genes Chromosomes Cancer. 2013 May;52(5):480-94. doi: 10.1002/gcc.22045. Epub 2013 Jan 23.
    • SULT1A1 gene deletion in BRCA2-associated male breast cancer: a link between genes and environmental exposures?
    • Palli D, Rizzolo P, Zanna I, Silvestri V, Saieva C, Falchetti M, Navazio AS, Graziano V, Masala G, Bianchi S, Russo A, Tommasi S, Ottini L.
    • J Cell Mol Med. 2013 May;17(5):605-7. doi: 10.1111/jcmm.12043.
    • DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.
    • Kamieniak MM, Muñoz-Repeto I, Rico D, Osorio A, Urioste M, García-Donas J, Hernando S, Robles-Díaz L, Ramón Y Cajal T, Cazorla A, Sáez R, García-Bueno JM, Domingo S, Borrego S, Palacios J, van de Wiel MA, Ylstra B, Benítez J, García MJ.
    • Br J Cancer. 2013 Apr 30;108(8):1732-42. doi: 10.1038/bjc.2013.141. Epub 2013 Apr 4.
    • No evidence for PALB2 methylation in high-grade serous ovarian cancer.
    • Mikeska T, Alsop K; Australian Ovarian Cancer Study Group, Mitchell G, Bowtell DD, Dobrovic A.
    • J Ovarian Res. 2013 Apr 12;6(1):26. doi: 10.1186/1757-2215-6-26.
    • Salpingectomy: Can removing the fallopian tubes lower ovarian cancer risk?
    • Ilana Cass, Doug Levine
    • FORCE. Be Empowered Webinars. 2013 Apr 11.
    • Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer.
    • Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H, Chatterton RT Jr, Sullivan ME, Hansen N, Bethke K, Zalles CM, Khan SA.
    • Cancer Prev Res (Phila). 2013 Apr;6(4):321-30. doi: 10.1158/1940-6207.CAPR-12-0304. Epub 2013 Mar 19.

    Press: Breast cancer gene test could allow preventive treatment. (The Telegraph)

    • Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
    • Reitsma W, Mourits MJ, de Bock GH, Hollema H.
    • Mod Pathol. 2013 Apr;26(4):572-8. doi: 10.1038/modpathol.2012.169. Epub 2012 Oct 19.
    • Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.
    • Zhang J, Shi Y, Lalonde E, Li L, Cavallone L, Ferenczy A, Gotlieb WH, Foulkes WD, Majewski J.
    • BMC Cancer. 2013 Mar 22;13:146. doi: 10.1186/1471-2407-13-146.
    • Male breast cancer, age and sex chromosome aneuploidy.
    • Jacobs PA, Maloney V, Cooke R, Crolla JA, Ashworth A, Swerdlow AJ.
    • Br J Cancer. 2013 Mar 5;108(4):959-63. doi: 10.1038/bjc.2012.577. Epub 2013 Jan 8.
    • Surgical implications of the potential new tubal pathway for ovarian carcinogenesis.
    • Chene G, Rahimi K, Mes-Masson AM, Provencher D.
    • J Minim Invasive Gynecol. 2013 Mar-Apr;20(2):153-9. doi: 10.1016/j.jmig.2012.11.010. Epub 2013 Jan 16.
    • Review
    • Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier.
    • Alanee S, Shah S, Murali R, Rau-Murthy R, Schrader KA, Offit K.
    • Fam Cancer. 2013 Mar;12(1):125-7. doi: 10.1007/s10689-012-9572-0.
    • Case report, Letter

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Should I test for Cowden?

    • 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
    • Pennington KP, Wickramanayake A, Norquist BM, Pennil CC, Garcia RL, Agnew KJ, Taniguchi T, Welcsh P, Swisher EM.
    • Gynecol Oncol. 2013 Mar;128(3):493-9. doi: 10.1016/j.ygyno.2012.12.007. Epub 2012 Dec 12.
    • Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271.
    • Köbel M, Ghatage P.
    • Int J Gynecol Pathol. 2013 Mar;32(2):176. doi: 10.1097/PGP.0b013e31826b4ea1.
    • Comment, Letter

    Case report:

    A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1.

    Letter, Reply:

    In reply.

    • HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
    • van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG, van der Wall E.
    • PLoS One. 2013;8(2):e56055. doi: 10.1371/journal.pone.0056055. Epub 2013 Feb 8.
    • Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
    • Hsu NC, Huang YF, Yokoyama KK, Chu PY, Chen FM, Hou MF.
    • PLoS One. 2013;8(2):e56256. doi: 10.1371/journal.pone.0056256. Epub 2013 Feb 6.
    • BRCA2 Dysfunction Promotes Malignant Transformation of Pancreatic Intraepithelial Neoplasia.
    • Wang Q, Liu H, Liu T, Shu S, Jiang H, Cheng S, Yuan Y, Yang W, Wang L.
    • Anticancer Agents Med Chem. 2013 Feb 1;13(2):261-9.
    • Determination of Molecular Markers for BRCA1 and BRCA2 Heterozygosity Using Gene Expression Profiling.
    • Salmon AY, Salmon-Divon M, Zahavi T, Barash Y, Levy-Drummer RS, Jacob-Hirsch J, Peretz T.
    • Cancer Prev Res (Phila). 2013 Feb;6(2):82-90. doi: 10.1158/1940-6207.CAPR-12-0105. Epub 2013 Jan 22.

    Research News:

    New test predicts BRCA1 and BRCA2 mutations.

    Press: The Future of BRCA1/BRCA2 Testing. (OncLive)

    • Genetics of Susceptibility to Sporadic Ovarian Cancer.
    • Katabathina VS, Prasad SR.
    • eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net. doi: 10.1002/9780470015902.a0023853. 2013 Feb.
    • Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
    • Wang YQ, Yan Q, Zhang JR, Li SD, Yang YX, Wan XP.
    • J Obstet Gynaecol Res. 2013 Feb;39(2):549-54. doi: 10.1111/j.1447-0756.2012.01979.x. Epub 2012 Sep 25.
    • Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.
    • Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS, Andrulis IL.
    • Clin Cancer Res. 2013 Jan 15;19(2):336-46. doi: 10.1158/1078-0432.CCR-11-3314. Epub 2012 Dec 4.
    • VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer.
    • http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053070Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A, Mangia A.
    • PLoS One. 2013;8(1):e53070. doi: 10.1371/journal.pone.0053070. Epub 2013 Jan 11.
    • BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    • Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, Berchuck A, Cerami E, Schultz N, Soslow RA.
    • Am J Surg Pathol. 2013 Jan;37(1):138-46. doi: 10.1097/PAS.0b013e31826cabbd.
    • Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    • Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.
    • Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21.
    • Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.
    • Muñoz-Repeto I, García MJ, Kamieniak M, Ramón Y Cajal T, Domingo S, Cazorla A, García Donas J, Hernando Polo S, García Sagredo JM, Hernández E, Lacambra C, Saez R, Robles L, Borrego S, Prat J, Palacios J, Benítez J.
    • Histol Histopathol. 2013 Jan;28(1):133-44.
    • HOX gene methylation status analysis in patients with hereditary breast cancer.
    • Pilato B, Pinto R, De Summa S, Lambo R, Paradiso A, Tommasi S.
    • J Hum Genet. 2013 Jan;58(1):51-3. doi: 10.1038/jhg.2012.118. Epub 2012 Oct 11.
    • PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
    • Deb S, Do H, Byrne D, Jene N; kConFab Investigators, Dobrovic A, Fox SB.
    • Breast Cancer Res. 2013;15(4):R69.
    • The ectopic expression of BRCA1 is associated with genesis, progression, and prognosis of breast cancer in young patients.
    • Zhang Q, Zhang Q, Cong H, Zhang X.
    • Diagn Pathol. 2012 Dec 31;7:181. doi: 10.1186/1746-1596-7-181.
    • Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations.
    • Rouault A, Banneau G, Macgrogan G, Jones N, Elarouci N, Barouk-Simonet E, Venat L, Coupier I, Letouzé E, de Reyniès A, Bonnet F, Iggo R, Sévenet N, Longy M.
    • PLoS One. 2012;7(12):e52079. doi: 10.1371/journal.pone.0052079. Epub 2012 Dec 21.
    • Mitochondrial DNA mutation in serous ovarian cancer: implications for mitochondria-coded genes in chemoresistance.
    • Guerra F, Perrone AM, Kurelac I, Santini D, Ceccarelli C, Cricca M, Zamagni C, De Iaco P, Gasparre G.
    • J Clin Oncol. 2012 Dec 20;30(36):e373-8. doi: 10.1200/JCO.2012.43.5933. Epub 2012 Nov 13.
    • Ovarian cancer molecular pathology.
    • Longuespée R, Boyon C, Desmons A, Vinatier D, Leblanc E, Farré I, Wisztorski M, Ly K, D'Anjou F, Day R, Fournier I, Salzet M.
    • Cancer Metastasis Rev. 2012 Dec;31(3-4):713-32. doi: 10.1007/s10555-012-9383-7.
    • Review
    • IGF-1 and BRCA1 signalling pathways in familial cancer.
    • Werner H, Bruchim I.
    • Lancet Oncol. 2012 Dec;13(12):E537-44. doi: 10.1016/S1470-2045(12)70362-5.
    • Review
    • BRCA2 promoter hypermethylation in sporadic breast cancer.
    • Bosviel R, Durif J, Guo J, Mebrek M, Kwiatkowski F, Bignon YJ, Bernard-Gallon DJ.
    • OMICS. 2012 Dec;16(12):707-10. doi: 10.1089/omi.2012.0060.
    • Hereditary ovarian cancer and two-compartment tumor metabolism: Epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.
    • Martinez-Outschoorn UE, Balliet RM, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP.
    • Cell Cycle. 2012 Nov 15;11(22):4152-66. doi: 10.4161/cc.22226. Epub 2012 Oct 9.
    • Proliferation in the Normal FTE Is a Hallmark of the Follicular Phase, Not BRCA Mutation Status.
    • George SH, Milea A, Shaw PA.
    • Clin Cancer Res. 2012 Nov 15;18(22):6199-207. doi: 10.1158/1078-0432.CCR-12-2155. Epub 2012 Sep 11.
    • Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation.
    • Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, Sigal-Zafrani B, Bollet M, Longy M, Houdayer C, Sastre-Garau X, Vincent-Salomon A, Stoppa-Lyonnet D, Stern MH.
    • Cancer Res. 2012 Nov 1;72(21):5454-62. doi: 10.1158/0008-5472.CAN-12-1470. Epub 2012 Aug 29.
    • Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer.
    • Coppola D, Nicosia SV, Doty A, Sellers TA, Lee JH, Fulp J, Thompson Z, Galeb S, McLaughlin J, Narod SA, Schildkraut J, Pal T.
    • Anticancer Res. 2012 Nov;32(11):4963-9.
    • E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.
    • Smith NL, Welcsh P, Press JZ, Agnew KJ, Garcia R, Swisher EM.
    • Genes Chromosomes Cancer. 2012 Nov;51(11):1054-62. doi: 10.1002/gcc.21990. Epub 2012 Aug 9.
    • Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
    • de la Cruz J, Andre F, Harrell RK, Bassett RL Jr, Arun B, Mathieu MC, Delaloge S, Gilcrease MZ.
    • Hum Pathol. 2012 Nov;43(11):1932-9. doi: 10.1016/j.humpath.2012.02.002. Epub 2012 May 14.
    • Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors.
    • Lu FI, Gilks CB, Mulligan AM, Ryan P, Allo G, Sy K, Shaw PA, Pollett A, Clarke BA.
    • Int J Gynecol Pathol. 2012 Nov;31(6):524-31. doi: 10.1097/PGP.0b013e31824fe2aa.
    • Comprehensive molecular portraits of human breast tumours.
    • Cancer Genome Atlas Network.
    • Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.

    Press: Study Divides Breast Cancer Into Four Distinct Types (New York Times)

    • Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers.
    • Kaplan JS, Schnitt SJ, Collins LC, Wang Y, Garber JE, Montgomery K, West RB, Krag K, Fetten K, Lincoln A, Tung NM.
    • Am J Surg Pathol. 2012 Oct;36(10):1483-8. doi: 10.1097/PAS.0b013e31825789ed.
    • Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
    • Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, Bulten J, Bol M.
    • Gynecol Oncol. 2012 Oct;127(1):88-93. doi: 10.1016/j.ygyno.2012.06.015. Epub 2012 Jun 16.
    • Peritoneal cytology in risk-reducing salpingo-oophorectomy: Implications for cancer outcomes.
    • Chen L, McAlhaney S, Fehniger J, Powell C, Crawford B, Mak J, Rabban J.
    • Gynecol Oncol. 2012 Oct;127(1 Suppl):S17. doi: 10.1016/j.ygyno.2012.07.047.
    • Conference abstract
    • Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
    • Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz AL, Lips EH.
    • Ann Oncol. 2012 Sep;23(9):2301-5. doi: 10.1093/annonc/mdr621. Epub 2012 Feb 21.

    Free text: Clinical Correlates of 'BRCAness' in Triple-Negative Breast Cancer of Patients Receiving Adjuvant Chemotherapy. (Medscape)

    • BRCA1 immunohistochemistry assay: can it play a role in assessing sporadic early-onset breast cancer?
    • Roehe AV, Boff AL, Damin A.
    • Breast J. 2012 Sep;18(5):500-1. doi: 10.1111/j.1524-4741.2012.01292.x. Epub 2012 Aug 16.
    • Letter
    • Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese.
    • Pang D, Zhao Y, Xue W, Shan M, Chen Y, Zhang Y, Zhang G, Liu F, Li D, Yang Y.
    • Med Oncol. 2012 Sep;29(3):1561-8. doi: 10.1007/s12032-011-0100-0. Epub 2011 Nov 11.
    • BRCA1--conductor of the breast stem cell orchestra: the role of BRCA1 in mammary gland development and identification of cell of origin of BRCA1 mutant breast cancer.
    • Buckley NE, Mullan PB.
    • Stem Cell Rev. 2012 Sep;8(3):982-93. doi: 10.1007/s12015-012-9354-y.
    • Review
    • BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
    • Bal A, Verma S, Joshi K, Singla A, Thakur R, Arora S, Singh G.
    • Virchows Arch. 2012 Sep;461(3):305-12. doi: 10.1007/s00428-012-1286-z. Epub 2012 Jul 21.
    • Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry.
    • Dite GS, Makalic E, Schmidt DF, Giles GG, Hopper JL, Southey MC.
    • Breast Cancer Res. 2012 Aug 28;14(4):R122. doi: 10.1186/bcr3248.
    • The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
    • Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Gruvberger-Saal SK, Saal LH, Holm K, Hegardt C, Arason A, Fagerholm R, Persson C, Grabau D, Johnsson E, Lövgren K, Magnusson L, Heikkilä P, Agnarsson BA, Johannsson OT, Malmström P, Fernö M, Olsson H, Loman N, Nevanlinna H, Barkardottir RB, Borg Å.
    • Cancer Res. 2012 Aug 15;72(16):4028-36. Epub 2012 Jun 15.
    • Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis.
    • Tone AA, Virtanen C, Shaw P, Brown TJ.
    • Clin Cancer Res. 2012 Aug 15;18(16):4334-44. doi: 10.1158/1078-0432.CCR-12-0199. Epub 2012 Jul 2.
    • Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.
    • Fujiwara M, McGuire VA, Felberg A, Sieh W, Whittemore AS, Longacre TA.
    • Am J Surg Pathol. 2012 Aug;36(8):1170-7. doi: 10.1097/PAS.0b013e31825d9b8d.
    • BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer.
    • Tammaro C, Raponi M, Wilson DI, Baralle D.
    • Biochem Soc Trans. 2012 Aug;40(4):768-72. doi: 10.1042/BST20120140.
    • Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours.
    • Walker LC, Krause L; kConFab Investigators, Spurdle AB, Waddell N.
    • Breast Cancer Res Treat. 2012 Aug;134(3):1005-11. Epub 2012 Mar 21.
    • Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification.
    • Kornegoor R, Moelans CB, Verschuur-Maes AH, Hogenes MCh, de Bruin PC, Oudejans JJ, van Diest PJ.
    • Breast Cancer Res. 2012 Jul 5;14(4):R101. doi: 10.1186/bcr3220.
    • Molecular insights on basal-like breast cancer.
    • Valentin MD, da Silva SD, Privat M, Alaoui-Jamali M, Bignon YJ.
    • Breast Cancer Res Treat. 2012 Jul;134(1):21-30. doi: 10.1007/s10549-011-1934-z. Epub 2012 Jan 11.
    • Review
    • Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
    • Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M.
    • Breast Cancer Res Treat. 2012 Jul;134(1):131-7. doi: 10.1007/s10549-011-1945-9. Epub 2012 Jan 8.
    • What drives breast cancer heterogeneity: oncogenic events or cell of origin?
    • Ginestier C, Charafe-Jauffret E, Birnbaum D.
    • J Pathol. 2012 Jul;227(3):267-9. doi: 10.1002/path.4028. Epub 2012 May 8.

    A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.

    • Expression of TopBP1 in hereditary breast cancer.
    • Forma E, Krzeslak A, Bernaciak M, Romanowicz-Makowska H, Brys M.
    • Mol Biol Rep. 2012 Jul;39(7):7795-804. doi: 10.1007/s11033-012-1622-z. Epub 2012 Apr 28.
    • Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.
    • Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, Massink MP, Waisfisz Q, Rottenberg S, Boven E, Jonkers J, Jimenez CR.
    • Mol Cell Proteomics. 2012 Jul;11(7):M111.013334. doi: 10.1074/mcp.M111.013334. Epub 2012 Feb 24.
    • Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene.
    • Tanic M, Yanowsky K, Rodriguez-Antona C, Andrés R, Márquez-Rodas I, Osorio A, Benitez J, Martinez-Delgado B.
    • PLoS One. 2012;7(6):e38847. doi: 10.1371/journal.pone.0038847. Epub 2012 Jun 11.
    • Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells.
    • Yu VM, Marion CM, Austria TM, Yeh J, Schönthal AH, Dubeau L.
    • Int J Cancer. 2012 Jun 1;130(11):2495-504. doi: 10.1002/ijc.26309. Epub 2011 Aug 29.
    • Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.
    • Holm K, Staaf J, Jönsson G, Vallon-Christersson J, Gunnarsson H, Arason A, Magnusson L, Barkardottir RB, Hegardt C, Ringnér M, Borg A.
    • Breast Cancer Res Treat. 2012 Jun;133(2):583-94. doi: 10.1007/s10549-011-1817-3. Epub 2011 Oct 16.
    • Evolutionary pathways in BRCA1-associated breast tumors.
    • Martins FC, De S, Almendro V, Gönen M, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, Garber JE, Fetten K, Michor F, Polyak K.
    • Cancer Discov. 2012 Jun;2(6):503-11. doi: 10.1158/2159-8290.CD-11-0325. Epub 2012 Apr 10.

    Comment:

    Tracking evolution of BRCA1-associated breast cancer.

    • Can a simple blood test really predict breast cancer?
    • McCartney M.
    • BMJ. 2012 May 15;344:e3374. doi: 10.1136/bmj.e3374.
    • News
    • Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.
    • Brennan K, Garcia-Closas M, Orr N, Fletcher O, Jones M, Ashworth A, Swerdlow A, Thorne H; KConFab Investigators, Riboli E, Vineis P, Dorronsoro M, Clavel-Chapelon F, Panico S, Onland-Moret NC, Trichopoulos D, Kaaks R, Khaw KT, Brown R, Flanagan JM.
    • Cancer Res. 2012 May 1;72(9):2304-13. Epub 2012 Feb 28.

    News: Epigenetic test could inform breast cancer risk prediction. (PHG Foundation)

    • Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
    • Okada S, Tokunaga E, Kitao H, Akiyoshi S, Yamashita N, Saeki H, Oki E, Morita M, Kakeji Y, Maehara Y.
    • Ann Surg Oncol. 2012 May;19(5):1499-507. doi: 10.1245/s10434-011-2166-5. Epub 2011 Dec 17.
    • Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutation.
    • Abd-Rabbo D, Abaji C, Cardin GB, Filali-Mouhim A, Arous C, Portelance L, Escobar E, Cloutier S, Tonin PN, Provencher DM, Mes-Masson AM, Maugard CM.
    • Cancer Prev Res (Phila). 2012 May;5(5):765-77. doi: 10.1158/1940-6207.CAPR-11-0547. Epub 2012 Mar 8.
    • The role of the fallopian tube in ovarian cancer.
    • Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J, Hoskins PJ, Stuart GC, Swenerton KD, Huntsman DG, Gilks CB, Miller DM, McAlpine JN.
    • Clin Adv Hematol Oncol. 2012 May;10(5):296-306.
    • The power of DNA double-strand break (DSB) repair testing to predict breast cancer susceptibility.
    • Keimling M, Deniz M, Varga D, Stahl A, Schrezenmeier H, Kreienberg R, Hoffmann I, König J, Wiesmüller L.
    • FASEB J. 2012 May;26(5):2094-104. doi: 10.1096/fj.11-200790. Epub 2012 Jan 25.
    • BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis.
    • Crum CP, McKeon FD, Xian W.
    • Int J Gynecol Cancer. 2012 May;22 Suppl 1:S29-34. doi: 10.1097/IGC.0b013e31824d7269.
    • A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1.
    • Maurac I, Sabol M, Musani V, Car D, Ozretic P, Kalafatic D, Oreskovic S, Babic D, Levanat S.
    • Int J Gynecol Pathol. 2012 May;31(3):264-71. doi: 10.1097/PGP.0b013e31823b6f0f.
    • Case Report

    Comment, Letter:

    Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271.

    • Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers.
    • Custodio A, López-Farré AJ, Zamorano-León JJ, Mateos-Cáceres PJ, Macaya C, Caldés T, de la Hoya M, Olivera E, Puente J, Díaz-Rubio E, Pérez-Segura P.
    • J Cancer Res Clin Oncol. 2012 May;138(5):867-75. doi: 10.1007/s00432-012-1161-y. Epub 2012 Feb 7.
    • Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases.
    • Martinez-Delgado B, Yanowsky K, Inglada-Perez L, de la Hoya M, Caldes T, Vega A, Blanco A, Martin T, Gonzalez-Sarmiento R, Blasco M, Robledo M, Urioste M, Song H, Pharoah P, Benitez J.
    • J Med Genet. 2012 May;49(5):341-4. Epub 2012 Apr 6.

    Free Full Text: Shorter Telomere Length Is Associated With Increased Ovarian Cancer Risk in Both Familial and Sporadic Cases. (Medscape Oncology)

    • BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
    • McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.
    • Mod Pathol. 2012 May;25(5):740-50. doi: 10.1038/modpathol.2011.211. Epub 2012 Jan 27.
    • Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
    • Yan M, Xu H, Waddell N, Shield-Artin K, Haviv I; kConFab authors, McKay MJ, Fox SB.
    • Breast Cancer Res. 2012 Apr 26;14(2):R69.
    • The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
    • Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S.
    • Nature. 2012 Apr 18;486(7403):346-52. doi: 10.1038/nature10983.

    Comment:

    Copy number aberrations define breast cancer subgroups.

    Comment:

    Who's driving anyway? Herculean efforts to identify the drivers of breast cancer.

    Comment:

    Genomics: the breast cancer landscape.

    Comment:

    The breast cancer genome and the complexity of different subgroups: what does it all mean?

    News: Genetic map leads to new thinking on breast cancer. (PHG Foundation)

    • Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    • Joosse SA, Brandwijk KI, Devilee P, Wesseling J, Hogervorst FB, Verhoef S, Nederlof PM.
    • Breast Cancer Res Treat. 2012 Apr;132(2):379-89. doi: 10.1007/s10549-010-1016-7. Epub 2010 Jul 8.
    • Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
    • Alford SH, Toy K, Merajver SD, Kleer CG.
    • Breast Cancer Res Treat. 2012 Apr;132(2):429-37. doi: 10.1007/s10549-011-1591-2. Epub 2011 May 26.
    • Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.
    • Nagel JH, Peeters JK, Smid M, Sieuwerts AM, Wasielewski M, de Weerd V, Trapman-Jansen AM, van den Ouweland A, Brüggenwirth H, van Ijcken WF, Klijn JG, van der Spek PJ, Foekens JA, Martens JW, Schutte M, Meijers-Heijboer H.
    • Breast Cancer Res Treat. 2012 Apr;132(2):439-48. doi: 10.1007/s10549-011-1588-x. Epub 2011 May 26.
    • Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
    • Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, Kauff ND, Levine DA.
    • Mod Pathol. 2012 Apr;25(4):625-36. doi: 10.1038/modpathol.2011.183. Epub 2011 Dec 23.
    • Promoter methylation status and expression of estrogen receptor alpha in familial breast cancer patients.
    • Wei J, Han B, Mao XY, Wei MJ, Yao F, Jin F.
    • Tumour Biol. 2012 Apr;33(2):413-20. doi: 10.1007/s13277-011-0234-x. Epub 2011 Sep 16.
    • APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.
    • Brough R, Bajrami I, Vatcheva R, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A.
    • EMBO J. 2012 Mar 7;31(5):1160-76. doi: 10.1038/emboj.2011.490. Epub 2012 Jan 31.
    • High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
    • Rzepecka IK, Szafron L, Stys A, Bujko M, Plisiecka-Halasa J, Madry R, Osuch B, Markowska J, Bidzinski M, Kupryjanczyk J.
    • Cancer Genet. 2012 Mar;205(3):94-100. doi: 10.1016/j.cancergen.2011.12.005.
    • Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers.
    • Primas H, Kroiss R, Kalteis K, Rappaport C, Muhr D, Primas C, Kubista E, Horvat R, Oefner P, Singer C, Wagner And The Austrian Hereditary Breast And Ovarian Cancer Group T.
    • Eur J Cancer Prev. 2012 Mar;21(2):199-204. doi: 10.1097/CEJ.0b013e32834c9b22.
    • Clinical implications for BRCA gene mutation in breast cancer.
    • Xu J, Wang B, Zhang Y, Li R, Wang Y, Zhang S.
    • Mol Biol Rep. 2012 Mar;39(3):3097-102. doi: 10.1007/s11033-011-1073-y. Epub 2011 Jun 21.
    • BRCA1 haploinsufficiency: consequences for breast cancer.
    • Salmena L, Narod S.
    • Womens Health (Lond Engl). 2012 Mar;8(2):127-9. doi: 10.2217/whe.12.2.
    • Commentary

    Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.

    • c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
    • Regan JL, Kendrick H, Magnay FA, Vafaizadeh V, Groner B, Smalley MJ.
    • Oncogene. 2012 Feb 16;31(7):869-83. doi: 10.1038/onc.2011.289. Epub 2011 Jul 18.
    • Role of micronucleus test in predicting breast cancer susceptibility: a systematic review and meta-analysis.
    • Cardinale F, Bruzzi P, Bolognesi C.
    • Br J Cancer. 2012 Feb 14;106(4):780-90. doi: 10.1038/bjc.2011.567. Epub 2011 Dec 20.
    • Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.
    • Bijron JG, van der Groep P, van Dorst EB, Seeber LM, Sie-Go DM, Verheijen RH, van Diest PJ.
    • Endocr Relat Cancer. 2012 Feb 13;19(1):69-81. doi: 10.1530/ERC-11-0338. Print 2012 Feb.

    Comment:

    Epigenetic modification and cancer: mark or stamp?

    • The breast cancer susceptibility gene BRCA2 is required for the maintenance of telomere homeostasis.
    • Min J, Choi ES, Hwang K, Kim J, Sampath S, Venkitaraman AR, Lee H.
    • J Biol Chem. 2012 Feb 10;287(7):5091-101. doi: 10.1074/jbc.M111.278994. Epub 2011 Dec 20.
    • Functional differences among BRCA1 missense mutations in the control of centrosome duplication.
    • Kais Z, Chiba N, Ishioka C, Parvin JD.
    • Oncogene. 2012 Feb 9;31(6):799-804. doi: 10.1038/onc.2011.271. Epub 2011 Jul 4.
    • Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    • Aysal A, Karnezis A, Medhi I, Grenert JP, Zaloudek CJ, Rabban JT.
    • Am J Surg Pathol. 2012 Feb;36(2):163-72. doi: 10.1097/PAS.0b013e31823bc434.
    • Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.
    • Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, Brachtel EF, Schapira L, Come SE, Winer EP, Partridge AH.
    • Breast Cancer Res Treat. 2012 Feb;131(3):1061-6. doi: 10.1007/s10549-011-1872-9. Epub 2011 Nov 13.
    • TLE3 Expression Is Associated with Sensitivity to Taxane Treatment in Ovarian Carcinoma.
    • Samimi G, Ring BZ, Ross DT, Seitz RS, Sutherland RL, O'Brien PM, Hacker NF, Huh WK.
    • Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):273-9. doi: 10.1158/1055-9965.EPI-11-0917. Epub 2011 Dec 22.
    • Tetraploidy in BRCA2 breast tumours.
    • Jonsdottir AB, Stefansson OA, Bjornsson J, Jonasson JG, Ogmundsdottir HM, Eyfjord JE.
    • Eur J Cancer. 2012 Feb;48(3):305-10. doi: 10.1016/j.ejca.2011.11.008. Epub 2011 Nov 29.
    • Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers.
    • Hopper JL, Jenkins MA, Dowty JG, Dite GS, Apicella C, Keogh L, Win AK, Young JP, Buchanan D, Walsh MD, Rosty C, Baglietto L, Severi G, Phillips KA, Wong EM, Dobrovic A, Waring P, Winship I, Ramus SJ, Giles GG, Southey MC.
    • Pathology. 2012 Feb;44(2):89-98. doi: 10.1097/PAT.0b013e32834e8e5b.
    • Review
    • Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.
    • Heravi-Moussavi A, Anglesio MS, Cheng SW, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan AN, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee CH, Zhao C, Young RH, Aparicio SA, Sorensen PH, Woo MM, Boyd N, Jones SJ, Hirst M, Marra MA, Gilks B, Shah SP, Foulkes WD, Morin GB, Huntsman DG.
    • N Engl J Med. 2012 Jan 19;366(3):234-42. doi: 10.1056/NEJMoa1102903. Epub 2011 Dec 21.

    Press: Gene Links Rare And Unrelated Cancers. (Medical News Today)

    • BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
    • Wysham WZ, Mhawech-Fauceglia P, Li H, Hays L, Syriac S, Skrepnik T, Wright J, Pande N, Hoatlin M, Pejovic T.
    • PLoS One. 2012;7(1):e30042. doi: 10.1371/journal.pone.0030042. Epub 2012 Jan 11.
    • Dysfunctional telomeres in human BRCA2 mutated breast tumors and cell lines.
    • Bodvarsdottir SK, Steinarsdottir M, Bjarnason H, Eyfjord JE.
    • Mutat Res. 2012 Jan 3;729(1-2):90-9. doi: 10.1016/j.mrfmmm.2011.10.002. Epub 2011 Oct 12.
    • Monozygotic twins discordant for constitutive BRCA1 promoter methylation, childhood cancer and secondary cancer.
    • Galetzka D, Hansmann T, El Hajj N, Weis E, Irmscher B, Ludwig M, Schneider-Rätzke B, Kohlschmidt N, Beyer V, Bartsch O, Zechner U, Spix C, Haaf T.
    • Epigenetics. 2012 Jan 1;7(1):47-54. doi: 10.4161/epi.7.1.18814. Epub 2012 Jan 1.
    • Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
    • Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, Stavropoulou A, Benítez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB; HEBON, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C; EMBRACE, Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schönbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L; GEMO Study Collaborators, Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Cañadas C, Heikkinen T, Heikkilä P, Aittomäki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S; kConFab Investigators, Rebbeck TR, Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K; SWE-BRCA Collaborators, Steele L, Neuhausen SL, Nussbaum R, Beattie M, Odunsi K, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2.
    • Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47. doi: 10.1158/1055-9965.EPI-11-0775. Epub 2011 Dec 5.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Article Request

    • Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
    • Vollebergh MA, Jonkers J, Linn SC.
    • Cell Mol Life Sci. 2012 Jan;69(2):223-45. doi: 10.1007/s00018-011-0809-0. Epub 2011 Sep 16.
    • Review
    • Presence of intratumoral stem cells in breast cancer patients with or without BRCA germline mutations.
    • Singer CF, Zabkova P, Rappaport C, Muhr D, Pfeiler G, Gschwantler-Kaulich D, Fink-Retter A, Staudigl C, Walter I, Hudelist G, Spiess AC, Kubista E.
    • Curr Cancer Drug Targets. 2012 Jan;12(1):44-50.
    • [Morphologic and immunohistochemical features of Fallopian tubes and ovaries in women with genetic predisposition to ovarian cancer].
    • Bilyk EA, Buchanskaia LG, Polishchuk LZ, Peëvich T.
    • Vopr Onkol. 2012;58(4):507-13.
    • [Article in Russian]